Conditions: Sarcoma
Keywords: Soft Tissue Sarcoma Adoptive Cell Therapy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
This is a single-arm trial that will evaluate the safety and feasibility of the Tumor-infiltrating lymphocyte (TIL) treatment and the persistence of TIL survival in vivo following treatment

Detailed description:

Arms:
arm 1: Participants will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be generated. All participants will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS). Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB). All participants will receive not less than 10\^9, and up to 1x10\^12 T cells in ≥250 mL NS as an inpatient by intravenously (IV).

Eight (8) to sixteen (16) hours after completing the T cell infusion, all participants will receive high-dose interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an intravenous bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as tolerated.

Interventions: intervention 1: TIL intervention 2: Interleukin-2 intervention 3: Fludarabine intervention 4: Cyclophosphamide
Intervention descriptions: intervention 1: Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated. intervention 2: Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 8 to 16 hours after T-cell infusion. intervention 3: Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion intervention 4: Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion

Protocol document:
Prot_SAP_000.pdf: 
 
 
A Phase I Trial of Lymphodepletion plus Adoptive Cell Therapy with High-Dose IL-2 in 
Adolescent and Young Adult Patients with Soft Tissue Sarcoma 
Protocol Number: 19837 
NCT Identified Number: NCT04052334 
 
Principal Investigator: 
John E. Mullinax, MD 
IND/IDE Sponsor/IND number: 
IND -18646 
Biostatistician: 
Michael J. Schell, PhD 
Medical Oncologist: 
Damon Reed, MD; Mihaela Druta, MD; Andrew Brohl, MD 
Radiation Oncologist: 
Arash Naghavi, MD 
Pathologist: 
Marilyn Bui, MD; Evita Henderson-Jackson, MD 
Radiologist: 
Jamie Caracciolo, MD; Rikesh Makanji, MD 
Medical monitor (if applicable) 
 
Funded by: 
Iovance Biotherapeutics 
Moffitt Cancer Center 
V Foundation 
 
Draft or Version Number: v9 January 21, 2022


  
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
ii 
Table of Contents 
1 
STATEMENT OF COMPLIANCE ...................................................................................... v 
1 
PROTOCOL SUMMARY.................................................................................................. 6 
1.1 
Synopsis ................................................................................................................. 6 
1.2 
Schema ................................................................................................................... 8 
1.3 
Schedule of Activities (SoA) .................................................................................... 9 
2 
INTRODUCTION ............................................................................................................11 
2.1 
Study Rationale ......................................................................................................11 
2.2 
Background ............................................................................................................12 
2.2.1 
Initial Studies of the Immune Infiltrate in Soft Tissue Sarcoma ...............12 
2.2.2 
Initial studies of adoptive T-cell transfer for the treatment of human 
cancer 
12 
2.2.3 
Addition of nonmyeloablative lymphodepletion to adoptive cell transfer ..13 
2.3 
Risk/Benefit Assessment ........................................................................................15 
2.3.1 
Known Potential Risks ............................................................................15 
2.3.2 
Known Potential Benefits ........................................................................16 
2.3.3 
Assessment of Potential Risks and Benefits ...........................................16 
3 
OBJECTIVES AND ENDPOINTS ...................................................................................16 
4 
STUDY DESIGN .............................................................................................................17 
4.1 
Overall Design ........................................................................................................17 
4.2 
Scientific Rationale for Study Design ......................................................................18 
4.3 
Justification for Dose ..............................................................................................18 
4.4 
End of Study Definition ...........................................................................................18 
5 
STUDY POPULATION ....................................................................................................19 
5.1 
Inclusion Criteria: 2-Step Design ............................................................................19 
5.1.1 
Step 1: Initiation of TIL Expansion ..........................................................19 
5.1.2 
Step 2: Chemotherapy/Cell Infusion Inclusion Criteria ............................19 
5.2 
Exclusion Criteria ...................................................................................................20 
5.2.1 
Exclusion Criteria Step 1: Initiation of TIL Expansion ..............................20 
5.3 
Lifestyle Considerations .........................................................................................21 
5.4 
Screen Failures ......................................................................................................21 
5.5 
Strategies for Recruitment and Retention ...............................................................21 
6 
STUDY INTERVENTION ................................................................................................22 
6.1 
Study Intervention(s) Administration .......................................................................22 
6.1.1 
Study Intervention Description ................................................................22 
6.1.2 
Dosing and Administration ......................................................................27 
6.2 
Preparation/Handling/Storage/Accountability .........................................................33 
6.2.1 
Acquisition and accountability .................................................................33 
6.2.2 
Formulation, Appearance, Packaging, and Labeling ...............................34 
6.2.3 
Product Storage and Stability .................................................................34 
6.2.4 
Preparation .............................................................................................34 
6.3 
Measures to Minimize Bias: Randomization and Blinding .......................................34 
6.4 
Study Intervention Compliance ...............................................................................34 
6.5 
Concomitant Therapy .............................................................................................35 
6.5.1 
Rescue Medicine ....................................................................................35 


  
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
iii 
7 
STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ........................................................................................35 
7.1 
Discontinuation of Study Intervention .....................................................................35 
7.2 
Participant Discontinuation/Withdrawal from the Study ...........................................36 
7.3 
Lost to Follow-Up ...................................................................................................36 
8 
STUDY ASSESSMENTS AND PROCEDURES ..............................................................37 
8.1 
SAFETY Assessments ...........................................................................................37 
8.1.1 
Treatment – Chemotherapy/Cell Infusion ...............................................37 
8.1.2 
Treatment Plan .......................................................................................37 
8.1.3 
Evaluation During Study .........................................................................40 
8.1.4 
Retreatment ...........................................................................................41 
8.2 
Other Assessments ................................................................................................41 
8.3 
BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES OR OTHER 
ENDPOINTS ..........................................................................................................................41 
8.4 
Adverse Events and Serious Adverse Events.........................................................41 
8.4.1 
Definition of Adverse Events (AE)...........................................................41 
8.4.2 
Definition of Serious Adverse Events (SAE) ...........................................41 
8.4.3 
Classification of an Adverse Event .........................................................42 
8.4.4 
Time Period and Frequency for Event Assessment and Follow-Up ........44 
8.4.5 
Adverse Event Reporting ........................................................................45 
8.4.6 
Serious Adverse Event Reporting ...........................................................45 
8.4.7 
Reporting Events to Participants ............................................................46 
8.4.8 
Events of Special Interest .......................................................................46 
8.4.9 
Reporting of Pregnancy ..........................................................................47 
8.5 
Unanticipated Problems .........................................................................................47 
8.5.1 
Definition of Unanticipated Problems (UP) ..............................................47 
8.5.2 
Unanticipated Problem Reporting ...........................................................48 
8.5.3 
Reporting Unanticipated Problems to Participants ..................................48 
9 
STATISTICAL CONSIDERATIONS ................................................................................48 
9.1 
Statistical Hypotheses ............................................................................................49 
9.2 
Sample Size Determination ....................................................................................49 
9.3 
Populations for Analyses ........................................................................................49 
9.4 
Statistical Analyses ................................................................................................49 
9.4.1 
General Approach ..................................................................................49 
9.4.2 
Analysis of the Primary Efficacy Endpoint(s) ..........................................49 
9.4.3 
Analysis of the Secondary Endpoint(s) ...................................................50 
9.4.4 
Safety Analyses ......................................................................................51 
9.4.5 
Baseline Descriptive Statistics ................................................................51 
9.4.6 
Planned Interim Analyses .......................................................................51 
9.4.7 
Sub-Group Analyses ..............................................................................51 
9.4.8 
Tabulation of Individual participant Data .................................................51 
9.4.9 
Exploratory Analyses ..............................................................................51 
10 
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS .............52 
10.1 
Regulatory, Ethical, and Study Oversight Considerations .......................................52 
10.1.1 
Informed Consent Process .....................................................................52 
10.1.2 
Study Discontinuation and Closure .........................................................53 


  
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
iv 
10.1.3 
Future Use of Stored Specimens and Data ............................................53 
10.1.4 
Key Roles and Study Governance ..........................................................54 
10.1.5 
Safety Oversight .....................................................................................54 
10.1.6 
Clinical Monitoring ..................................................................................54 
10.1.7 
Quality Assurance And Quality Control ...................................................55 
10.1.8 
Data Handling and Record Keeping .......................................................55 
10.1.9 
Protocol Deviations ................................................................................56 
10.1.10 
Publication and Data Sharing Policy .......................................................56 
10.1.11 
Conflict of Interest Policy ........................................................................57 
10.2 
Additional Considerations .......................................................................................57 
10.3 
Abbreviations .........................................................................................................58 
10.4 
Protocol Amendment History ..................................................................................60 
11 
REFERENCES ...............................................................................................................62 
12 
APPENDICES .................................................................................................................64 
12.1 
Appendix A .............................................................................................................65 
12.2 
Appendix B .............................................................................................................67 
12.3 
Appendix C ............................................................................................................70 
12.4 
Appendix D ............................................................................................................72 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
v 
1 
STATEMENT OF COMPLIANCE 
The trial will be conducted in accordance with the ICH E6, the Code of Federal Regulations on the 
Protection of Human Subjects (45 CFR Part 46), and the Supporting Agency Terms. The Principal 
Investigator will assure that no deviation from, or changes to the protocol will take place without 
prior agreement from the sponsor and documented approval from the Institutional Review Board, 
except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel 
involved in the conduct of this study have completed Human Subjects Protection Training. 
I agree to ensure that all staff members involved in the conduct of this study are informed of their 
obligation to meet the above commitments. 
Principal Investigator:  
 John E. Mullinax, MD Print/Type Name 
                                           Signed:   
                 Date:  


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
6 
1 
 
PROTOCOL SUMMARY 
1.1 SYNOPSIS  
Title: 
Phase I Trial of Lymphodepletion plus Adoptive Cell Therapy with 
High-Dose IL-2 in Adolescent and Young Adult Patients with Soft 
Tissue Sarcoma 
Study Description: 
Advanced sarcoma patients have few systemic treatment options, 
leading to a median survival expectation of only 1 year. Novel 
treatment approaches leveraging the adaptive immune response 
may offer some hope of improved outcomes. Preclinical evidence 
and results from this treatment approach with a similarly 
heterogenic solid tumor type, metastatic melanoma, are 
encouraging. Therefore, we hypothesize that use of tumor-
infiltrating lymphocytes from within soft tissue sarcoma in an 
adoptive cell therapy approach will yield improved outcomes for 
advanced sarcoma patients. Before testing this hypothesis, the 
safety and tolerability of this treatment approach must be 
established. 
Objectives: 
 
 
Primary Objective: To determine the safety and feasibility of 
treatment with adoptively transferred tumor-specific T cells 
following nonmyeloablative lymphodepleting chemotherapy 
followed by high-dose IL-2 for patients with advanced sarcoma. 
 
Secondary Objectives:  
1. To observe the objective antitumor responses per RECIST v1.1 
criteria 
2. To evaluate the degree of sustained persistence of infused T 
cells 
Endpoints: 
 
Primary Endpoint: Patients able to safely tolerate infusion of TIL 
and subsequent IL-2, as measured by adverse event rate 
 
Secondary Endpoints:  


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
7 
1. Objective response (CR + PR) rate at 12 weeks following TIL 
infusion, as measured by RECIST v1.1 
2. Persistence of TIL infusion product at 6 weeks following 
treatment, as measured by TCR repertoire comparison between 
the infusion product and circulating PBMC 
Study Population: 
Up to 15 patients, male and female, aged 18 to 39 years 
Phase: 
Phase I 
Description of 
Sites/Facilities 
Enrolling 
Participants: 
The H. Lee Moffitt Cancer Center and Research Institute, a high-
volume, NCI-designated Comprehensive Cancer Center in Tampa, 
FL. 
Description of 
Study Intervention: 
Patients will undergo resection of a soft tissue sarcoma from which  
tumor-infiltrating lymphocytes will be cultured and expanded.  This 
expanded TIL product will be infused following, nonmyeloablative 
lymphodepleting chemotherapy.  High-dose IL-2 will be given after 
TIL infusion to support the cell product expansion. 
Study Duration: 
22 months 
Participant 
Duration: 
12 months 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
8 
1.2 SCHEMA 
 
Treatment 
Days -7 and -6: 
Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 
2 hours. Mesna 20 mg/kg with D5W or NS at 125 mL/hour, infused IV over 24 hours. 
Days -5 to Day -1: 
Fludarabine 25 mg/m2 IV piggyback daily over approximately 30 minutes for 5 days. 
Day 0: 
T-cell infusion in 250 to 1000 mL NS over approximately 15 to 60 minutes depending on the volume to 
be infused. The rate of infusion may be adjusted based upon criteria listed in the adoptive cell therapy 
standard operating procedure (SOP). Vital signs (temperature, blood pressure, pulse, and respiratory 
rate) and pulse oximetry will be monitored per inpatient unit protocol following cell infusion and IL-2 
administration. 
Days 1 to 5: 
High-dose IL-2, 600 000 IU/kg IV bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, 
beginning approximately 8 to 16 hours after T-cell infusion. 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
9 
1.3 SCHEDULE OF ACTIVITIES (SOA) 
 
 
 
 
 
Hospital Stay 
 
Hospital Stay 
 
 
 
 
Assessment 
 
Screen 
D -28* 
D -14 
D -7 
D -6 
D -5 
D 0 
 
D 1 
Day 21 
(+/7 
days) 
D 42 
(+/- 7 
days) 
D 84 
(+/- 7 
days) 
Every 3 
mos for 12 
mos (+/- 
14 days) 
Informed consent 
• 
 
 
 
 
 
 
 
 
 
 
 
Medical history 
• 
 
• 
 
 
 
• 
 
• 
• 
• 
• 
Current medications 
• 
 
• 
• 
 
 
• 
 
• 
 
 
• 
Physical Exam 
• 
 
• 
• 
 
 
• 
 
• 
• 
• 
• 
Vital Signs 
• 
 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Performance Status 
• 
 
• 
 
 
 
• 
 
• 
 
 
• 
Baseline Symptom Assessment 
• 
 
 
 
 
 
 
 
 
 
 
 
MUGA and PFT (1, 4) 
• 
 
 
 
 
 
 
 
 
 
 
 
EKG (3) 
• 
 
• 
 
 
 
 
 
 
•(3) 
•(3) 
•(3) 
Blood Tests (1) 
 
 
 
 
 
 
 
 
 
 
 
 
CBC with diff, CMP 
• 
 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
LDH  
• 
 
• 
 
 
 
 
 
 
• 
• 
• 
Blood clotting tests (PT/PTT)  
• 
 
• 
 
 
 
 
 
 
 
 
 
HLA typing (if not done before) (2) 
• 
 
 
 
 
 
 
 
 
 
 
 
EBV ab 
• 
 
 
 
 
 
 
 
 
 
 
 
Hepatitis B and C, HTLV-1 & 2  
• 
 
 
 
 
 
 
 
 
 
 
 
HIV, RPR (FTA if necessary) (7) 
• 
 
 
 
 
 
 
 
 
 
 
 
Thyroid Tests (Free T4, TSH) (8) 
• 
 
• 
 
 
 
• 
 
• 
 
 
• 
Pregnancy Test (5) 
• 
 
• 
• 
 
 
 
 
• 
 
 
• 
PBMC Collection (14) 
 
• 
 
 
 
 
 •(q 1 wk x 5) 
  
• 
 
• 
• 
Immunodeficiency Panel 
 
 
 
 
 
 
 
 
 
 
• 
 
Radiography Tests: CT Chest-Abdomen-
Pelvis,(1, 6) 
• 
 
• 
 
 
 
 
 
 
• 
• 
• 
Tumor sample/biopsy for TIL 
 
• 
 
 
 
 
 
 
 
 
 
 
Adverse Event Assessment (9) 
 
 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Urinalysis (10) 
• 
 
• 
 
 
• 
• 
 
• 
 
 
• 
Leukapheresis (16) 
 
 
• 
 
 
 
 
 
 
• 
 
 
Lymphodepletion: 
 
 
 
 
 
 
 
 
 
 
 
 
Cyclophosphamide (hospital x 2) (11, 12) 
 
 
 
• 
• 
 
 
 
 
 
 
 
Fludarabine (outpatient x 5) (11, 12) 
 
 
 
 
 
• 
 
 
 
 
 
 
Adoptive Transfer of TIL (13) 
 
 
 
 
 
 
• 
 
 
 
 
 
High dose IL-2  (hospital 7-10 days) 
 
 
 
 
 
 
 
• 
 
 
 
 
*Study treatment dates are approximate; precise days will depend on rate of TIL growth and patient’s 
clinical status.  
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
10 
Footnotes to the Treatment Schema 
1. 
At screening, all laboratory and imaging studies must be complete and satisfactory within 
30 days of signing the consent document with the exceptions of:  
a. 
HLA-typing will not be repeated if performed previously.  
b. 
Serum pregnancy test for women of child-bearing potential (see section 5.1.1) will 
be done within 7 days of screening for the trial, within 7 days of screening for 
chemotherapy.  
c. 
Pulmonary function tests (PFTs) and/or cardiac MUGA whose results are valid for 6 
months if performed previously unless there is an interval change in the patient’s 
clinical status determined by the Moffitt treating physician. 
d. 
CT imaging of the chest, abdomen and pelvis completed within 30 days prior to 
signing the consent may be used to confirm measurable disease per RESIST V1.1 
criteria, and may be used for screening eligibility.  
2. 
HLA typing will be sent at screening only if not done previously. 
3. 
EKGs will be obtained at screening for the trial, at screening for chemotherapy, at 6 and 12 
weeks after adoptive transfer of TIL, and then every three months for 18 months. 
4. 
PFTs are required at screening.  A cardiac MUGA scan will be done at screening in all 
patients in consideration of prior Adriamycin-containing chemotherapy regimens, 
considering the safe use of high dose IL-2. If PFTs and/or a cardiac MUGA scan have 
been done within 6 months of screening, they will not be repeated unless there is an 
interval change in the patient’s clinical status determined by the Moffitt treating physician.  
5. 
Serum or urine pregnancy test will be performed on women of child-bearing potential (see 
5.1.2) during screening and again prior to initiation of chemotherapy. 
6. 
CT scans of chest, abdomen, pelvis, and other areas will be done as outlined in the 
schedule of activities, or as judged appropriate by the treating physician or PI. For patients 
with CT IV contrast allergy, appropriate premedication, use of MRI or CT without IV 
contrast will be undertaken at the discretion and judgment of the ordering physician. 
Clinical visits after each of the scans will also include documentation of size and location of 
palpable lesions. 
7. 
FTA only if RPR is positive 
8. 
If T4 and TSH are abnormal, thyroid workup will be done.  
9. 
Adverse events will be collected per section 8.4 throughout the study protocol beginning at 
initiation of treatment (day -28) and continuing at each treatment visit detailed in the study 
treatment schema until any one of the following:  progression, loss to follow-up, withdrawal 
of consent, or death. Beyond 100 days from study treatment, subjects will continued to be 
followed for ongoing drug-related adverse events until resolved, return to baseline, 
deemed irreversible by the Moffitt treating physician, or until the subject is lost to follow-up, 
there is withdrawal of study consent, removal of the subject from the trial by the Moffitt 
treating physician, or start of a subsequent anti-cancer therapy. 
10. 
Urinalysis will be done as indicated in the study calendar with the day -14 result used for 
Chemotherapy/Cell Infusion inclusion criteria. 
11. 
Cyclophosphamide will be administered on Days -7 and -6, fludarabine will be 
administered on Days -5 to -1. CBC with differential and CMP will be performed every day 
of treatment during preparative cyclophosphamide/fludarabine and TIL/high dose IL-2 
therapy per section 8.1.1. 
12. 
Within 4 weeks prior to the initiation of chemotherapy, patients will undergo physical 
examination and documentation of size and location of measurable lesions where 
applicable. The timing of the start of the lymphodepleting regimen of cyclophosphamide 
and fludarabine is subject to change depending upon the rate of the TIL growth. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
11 
13. 
Adoptive transfer will take place at day 0. 
14. 
60 mL of PBMC will be collected as defined in the schedule of activities. On day 0, only 
10mL of PBMC will be collected. Of note, if apheresis sample cannot be collected on day 
42 due to a technical issue, then an additional venipuncture for 60 mL peripheral blood 
mononuclear cells will be collected and used as a substitute. Samples will be used for 
immune monitoring and determination of TIL persistence with an informal comparison to 
results generated from our previous adoptive cell therapy trials that utilized the same 
collection schedule. Blood draws will be omitted for patients with symptomatic anemia or 
deemed not feasible by the PI and/or treating physician. 
15. 
Follow-up visits with disease evaluation will be conducted at days 42 and 84 (+/- 7 days) 
after TIL infusion, then every 90 days (+/- 14 days) for 12 months thereafter or until 
disease progression, withdrawal of consent, loss to follow-up, or death, whichever occurs 
first. After confirmed disease progression subjects will be followed every 3 months (+/- 4 
weeks) for overall survival and report of any subsequent anti-cancer treatments. This can 
be accomplished by visit, phone or email contact. 
16. 
Apheresis will be performed at day -14 and at day 42 (+/- 7 days). These samples will be 
used for immune monitoring purposes and determination of TIL persistence by comparing 
TCR clonality to the TIL infusion product. 
 
2 
 
INTRODUCTION 
 
2.1 STUDY RATIONALE  
Patients with advanced sarcoma have limited effective systemic treatment options available to them 
and are often young, falling into either the pediatric or young adult age groups. With current treatment 
options, patients can expect a median response duration of only 9 months and median survival of only 
1 year. Because of the youth of those affected, death from sarcoma results in a significant loss of 
productive life years. 
Novel approaches leveraging the adaptive immune response have been developed for several 
malignancies. Collectively termed “immunotherapy,” there are two broad approaches. First, 
monoclonal antibody therapy is used to reverse tumor-specific immune suppression directly. This has 
demonstrated efficacy for melanoma, renal cell carcinoma, and non-small cell lung cancer, and a 
plethora of open protocols have accrued for other disease states. Second, cellular immunotherapy 
strategies exist that seek to actively transfer a complement of tumor-specific T-cells into a patient, with 
the goal of enacting a living therapy that produces a very durable response. 
Within the cellular immunotherapy approaches, some investigators have chosen to genetically modify 
T-cells towards a tumor-specific antigen target. This approach has been dramatically effective for 
hematologic malignancies but not solid tumors, possibly because of the general clonal nature of 
hematologic malignancies, in contrast to the incredible heterogeneity of solid tumors. Another 
approach is to use tumor-infiltrating lymphocytes (TILs) from within solid tumors as cellular therapy. 
The goal of this treatment approach, called adoptive cell therapy (ACT), is to circumvent suppressive 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
12 
or tolerogenic influences in vivo through expansion of TILs ex vivo, followed by adoptive transfer. This 
has been shown to be effective for patients with metastatic melanoma, and there are currently open 
trials using this approach for squamous cell carcinoma of the cervix, squamous cell carcinoma of the 
head and neck, and non-small cell lung cancer. We believe that the ACT approach is superior due to 
the polyclonal nature of the cell product which better matches the heterogeneity of solid tumors. This 
has been borne out in clinical studies in which the TILs approached a response rate of nearly 40% for 
metastatic melanoma patients[1-4], whereas the success rate for gene-modified T-cell approaches in 
solid tumor patients has been much lower [5, 6]. 
We recently completed a pilot project that has generated preclinical data supporting the use ACT for 
patients with sarcoma. This project was undertaken using protocols developed in and validated by our 
significant melanoma ACT experience. In this project, we were able to successfully grow TILs from 
resected adult primary sarcoma specimens. The TILs grown from these specimens were expanded to 
a clinically meaningful number, and there was antitumor activity when the TILs were co-cultured with 
autologous tumor digest or human leukocyte antigen- (HLA-) matched sarcoma cell lines. 
We hypothesize that ACT for patients with advanced soft tissue sarcoma will be safe and well-
tolerated.   Furthermore, we expect that the culture and expansion of this product is feasible based on 
preclinical laboratory work.  We also hypothesize that the infusion of this TIL product will yield 
improved outcomes for advanced sarcoma patients. 
 
2.2 BACKGROUND  
 
2.2.1 INITIAL STUDIES OF THE IMMUNE INFILTRATE IN SOFT TISSUE SARCOMA 
We recently completed a pilot protocol, funded by the Chotiner Foundation, which focused on the 
immune infiltrate of 37 adult (> 18 years old) patient-derived sarcoma specimens acquired from 
3/2015 to 6/2017. Eleven different subtypes of sarcoma were identified, 78% of the tumors were high 
grade, 27% were recurrent, and 38% of patients had had preoperative therapy. An average of 48% 
(range, 3.6-76) cells in the tumor digest from the lymphocyte gate were CD3+ and TILs were grown 
from at least one fragment of all specimens. The phenotype of the CD3+ subpopulations from TIL 
cultures included an average 58% (range, 7-97) CD8+ and 19% (range 2-79) CD4+ cells. There was 
dramatic heterogeneity among patient TIL cultures. The function of expanded TILs has been tested, 
and an ELISA assay has identified tumor-specific function, as measured by interferon-gamma release 
after co-culture with an autologous tumor digest. 
2.2.2 INITIAL STUDIES OF ADOPTIVE T-CELL TRANSFER FOR THE TREATMENT OF 
HUMAN CANCER 
The identification of T cells with the ability to specifically recognize melanoma antigens, along with the 
technological capability to expand these tumor-reactive T cells to large numbers in the laboratory, has 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
13 
led to the development of adoptive transfer protocols for patients with metastatic melanoma. TILs 
derived from resected tumors that were expanded in vitro were shown to be capable of specifically 
recognizing tumor antigens, particularly MART-1, in over two-thirds of melanoma patients[7, 8]. Such 
TILs, when expanded to large numbers (greater than 10 billion) and adoptively transferred 
intravenously to patients along with IL-2, resulted in an objective response rate of 35% [9, 10]. This 
response rate was nearly twice that observed with IL-2 alone and was also seen in patients that were 
refractory to IL-2 treatment. 
In the first description of ACT, published in Science by the NCI Surgery Branch, 6 out of 13 patients 
demonstrated objective tumor regression, and 4 additional patients showed mixed responses, with 
substantial shrinkage of some lesions after lymphoid depletion and adoptive transfer of highly 
selected expanded tumor-reactive TILs and IL-2 [10]. Significant levels of tumor regression were 
observed in metastatic deposits in the liver, lungs, cutaneous and subcutaneous tissues, and lymph 
nodes. One patient had dramatic regression of axillary, pelvic and intraabdominal metastases, on-
going at 17 months, and was rendered free of disease by a surgical removal of one residual 
intraperitoneal lesion. Two other patients had marked, persistent lymphocytosis up to 3 weeks after 
the TIL infusion. Molecular and immunological analyses confirmed that these lymphocytes from their 
peripheral blood were the progeny of the infused TIL [10]. In particular, in one patient, it was shown 
that one specific clone repopulated this patient’s peripheral blood lymphocytes (PBL) up to 2 months 
after infusion. Immunohistochemistry studies revealed that specific clones from infused bulk 
oligoclonal TIL cells infiltrated the regressing tumor nodules. Although the mechanism for the 
continued proliferation in vivo of these rapidly expanded bulk TIL cells and their antitumor effects 
remain to be determined, it appears that some cells in the expanded bulk TIL might have provided 
necessary cytokines (such as IL-2) for cytotoxic T lymphocytes to persist and survive in vivo and 
eventually kill the tumor. Alternatively, the chemotherapy regimen used in this protocol might have 
depleted endogenous suppressive lymphocytes. 
Our institution has published 2 reports of our experience with ACT in patients with metastatic 
melanoma. The first experience described the infusion of TILs followed by high-dose IL-2 after a 
nonmyeloablative lymphodepleting chemotherapy regimen administered in a manner identical to the 
NCI experience. There were 5 objective responses among the 13 patients treated (38%), which was a 
similar rate of efficacy to that uncovered by the NCI experience [4]; however, progression during cell 
preparation (6/19, 21%) was a limiting factor and the response rate by intention-to-treat analysis was 
26%. A strategy was developed that added ipilimumab, a monoclonal antibody against cytotoxic T-
lymphocyte–associated antigen-4 (CTLA-4) to the treatment before TIL harvest and during cell 
preparation. In this experience, the attrition due to progression was decreased to 7% and the 
response, by intention-to-treat analysis, was increased to 38.5% from 26% in the first experience [3]. 
2.2.3 ADDITION OF NONMYELOABLATIVE LYMPHODEPLETION TO ADOPTIVE CELL 
TRANSFER 
These collective results suggest that the nonmyeoablative, lymphodepleting chemopreparative 
regimen identical to that which is proposed in this current study can be tolerated for up to 2 full cycles 
and is potentially efficacious for the treatment of advanced metastatic disease. This may be due to the 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
14 
homeostatic vacuum created by the chemotherapy regimen. After ablation of the endogenous 
lymphocyte compartment, the infused TIL cells may expand better in vivo without competition from 
endogenous lymphocytes. At the NIH, marked proliferation of the transferred TIL cells was not 
observed without this course of chemotherapy. It also appears that patients treated with the 
preparative regimen sustained lesser toxicities and tolerated more cycles of intravenous high-dose IL-
2 that patients receiving IL-2 without non-myeoablative lymphodepleting chemotherapy. Thus, in the 
proposed study, the plan is to administer this preparative lymphodepleting chemotherapy regimen to 
patients prior to TIL cell infusion. 
Mounting evidence suggests that the host immune environment can significantly impact the efficacy of 
adoptive cell transfer therapy. Data from mouse tumor models have demonstrated that sublethal 
doses of irradiation prior to adoptive transfer of tumor antigen-specific lymphocytes substantially 
increases the persistence and antitumor activity of the transferred cells [11]. While the mechanisms 
leading to this enhanced T-cell activity have not been precisely delineated, 2 non-mutually exclusive 
hypotheses may provide explanation. A subset of CD4+ T cells, expressing high levels of CD25 and 
the molecule FOXp3 and known as regulatory or suppressor T cells, is thought to have a negative 
impact on the activity of cytotoxic T cells in vivo [12, 13]. It has been hypothesized that increased 
numbers of suppressor T cells in cancer patients may correlate with an unfavorable prognoses and 
that elimination of these cells may result in an improved efficacy of adoptive immunotherapy [14-17].  
Alternatively, prior depletion of lymphocytes may create ‘space’ for the adoptively transferred cells 
within the lymphocyte compartment [18]. Under this model, homeostatic lymphocyte survival may 
result in increased proliferation and enhanced survival of transferred T cells, perhaps through a 
mechanism involving increased access to endogenous cytokines like IL-7 and IL-15 [19]. 
Traffic of TILs to tumor sites was evaluated by labeling TIL with indium-111 and performing sequential 
radionuclide scans. Of 26 patients who received cyclophosphamide, TIL trafficking to tumor was seen 
in 21 patients (81%), which was greater than the TIL trafficking to tumor that was seen in the 42% of 
patients who did not receive cyclophosphamide (p = .026). No differences were seen in tumor 
regression rates. Thus, even with a mild and very transient leukopenia (about 5 days), evidence of 
increased lymphocyte trafficking to tumor was observed [20]. 
The animal and clinical studies cited above strongly suggest that the clinical effectiveness of these 
cells and their abilities to survive and repopulate the host would be enhanced if patients were 
significantly immunosuppressed by the depletion of lymphocytes prior to the adoptive transfer of 
lymphocytes. 
A recent clinical trial investigated the addition of a lymphodepleting conditioning regimen to adoptive 
cell transfer therapy in patients with metastatic melanoma. Patients received a lymphodepleting 
chemotherapy regimen consisting of high-dose cyclophosphamide and standard doses of fludarabine 
before administration of highly selected, expanded, tumor-reactive TILs and IL-2 [1, 2]. The 
lymphodepletion step resulted in a transient myelosuppression and the elimination of all circulating 
lymphocytes for approximately 1 week, after which time patients recovered endogenous marrow 
function and had reconstituted their lymphocyte compartments towards normal levels within 2 to 3 
weeks [21]. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
15 
Because of the immunosuppression of fludarabine, one of the patients who had clonal repopulation 
from infused TIL cells and a complete response of metastatic melanoma, developed Epstein-Barr 
virus- (EBV-) associated B cell lymphoma. This patient was EBV-naïve prior to the treatments. The 
potential source of EBV was thought to be multiple blood product transfusions after chemotherapy. 
The patient later died of complications from the treatment of his lymphoma. Another patient developed 
polyneuropathy manifested in vision blindness, and motor and sensory defects approximately 2 
months after chemotherapy. The etiology of this complication is unknown, but was possibly related to 
the fludarabine [1]. 
2.3 RISK/BENEFIT ASSESSMENT  
 
2.3.1 KNOWN POTENTIAL RISKS  
 
The resection of tumor followed by non-myeloablative chemotherapy, adoptive TIL therapy, and high 
dose IL-2 regimens in this protocol entail serious potential discomforts and hazards for the patient.  
Side effects of common drugs used in this non-myeloablative regimen include: 
Surgical Resection:  Risks of resection are specific to the operation required for each patient to 
acquire tumor from which to culture the TIL product.   General risks include infection, bleeding, injury 
to neurovascular structures or viscera, and venous thromboembolism.  Resections on this protocol 
are designed with the lowest possible morbidity and lesions are chosen that will yield tissue without 
undue risk and for this reason superficial soft tissue lesions will be the preferred resection site.  There 
are no specific inclusion or exclusion sites of harvest given that soft tissue sarcoma has a varied 
metastatic pattern between subtype histologies.  Prior research has shown that the acquisition of 
visceral tumors for the initiation of TIL culture is safe and feasible[22].   Data from our own institution 
on other adoptive cell therapy clinical trial protocols further supports the safety of this approach.  
Superficial soft tissue sites will be prioritized over deep lesions to limit morbidity and lung resections 
will be considered in patients without a focus of disease in the soft tissue.   Visceral and cavitary 
lesions will be obtained using a minimally invasive approach (i.e. video-assisted thoracoscopic 
surgery or laparoscopy) and open laparotomy or thoracotomy will not be used as a method to obtain 
tissue. 
Cyclophosphamide: Marrow suppression, nausea, mucositis, rash, hemorrhagic cystitis, myocardial 
damage, alopecia, infertility, nausea and vomiting, and Syndrome of Inappropriate Antidiuretic 
Hormone release.   
Fludarabine: Myelosuppression, fever and chills, nausea and vomiting, malaise, fatigue, anorexia, 
weakness, neurologic toxicity, and interstitial pneumonitis.  Serious opportunistic infections have 
occurred in CLL patients treated with fludarabine. 
Antimicrobials in general: Allergic reactions, renal impairment, nausea, vomiting, hepatic damage, 
marrow suppression.  
High Dose IL-2:  A variety of side effects have been associated with high-dose IL-2 administration in 
our experience at the NCI and a listing of these side effects in 652 patients who received 1,039 
treatment courses are listed in the Appendix D.  


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
16 
Adoptive cell therapy with TIL: a variety of side effects that potentially overlap with high dose IL2 have 
been associated with adoptive cell therapy in our experience and at the NCI. Prominent long-term 
side effects include: vitiligo, high frequency hearing loss, anemia and uveitis. 
2.3.2 KNOWN POTENTIAL BENEFITS 
While the design of this study is not to evaluate primarily the efficacy of this treatment, there is 
potential for response to ACT in patients with advanced soft tissue sarcoma.   Extrapolating from the 
experience with melanoma patients (which has been recapitulated in the laboratory setting), ACT can 
yield meaningful responses in approximately 40% of patients.   Notable among these responses is the 
durability of response compared to other treatments.    
 
2.3.3 ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
The patients enrolled on this trial have no other treatment options that are known to be effective.   Any 
treatment course pursued outside of this trial will entail risks generally equal to those on this trial with 
generally less benefit since most of the trial alternatives are first in human trials of novel compounds.   
The treatment strategy of this protocol is not new and therefore some expectation regarding efficacy 
can be extrapolated from the prior ACT trials in patients with advanced cancer.   Of note, the primary 
toxicity of this treatment is related to the IL-2 given after TIL infusion.   The end organ reversible 
toxicities seen in prior trials were demonstrated in patients much older than the cohort enrolled on this 
trial.   With superior end organ function of this patient cohort, the toxicity profile should be diminished. 
 
3 
OBJECTIVES AND ENDPOINTS 
 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR 
ENDPOINTS 
Primary 
 
 
To determine the safety and 
feasibility of treatment with 
adoptively transferred 
tumor-specific T cells 
following nonmyeloablative 
lymphodepleting 
chemotherapy followed by 
high-dose IL-2 for patients 
with advanced sarcoma. 
Patients able to safely tolerate study 
treatment dosage and procedures. 
While this treatment 
strategy has been 
used in other 
advanced 
malignancies, this trial 
represents the first 
use in soft tissue 
sarcoma.  Prior 
treatment of these 
patients and the 
starting material 
(metastatic tumor vs. 
tumor bearing LN) is 
unique, justifying a 
phase I approach. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
17 
OBJECTIVES 
ENDPOINTS 
JUSTIFICATION FOR 
ENDPOINTS 
Secondary 
 
 
1. To observe the objective 
antitumor responses per 
RECIST v1.1 criteria 
 
1. Objective response (CR + PR) rate at 
12 weeks following TIL infusion, as 
measured by RECIST v1.1 
Evaluate the efficacy 
of the infusion product 
and possible 
justification for 
subsequent phase 2 
trial 
2. To evaluate the degree of 
sustained persistence of 
infused T cells 
2. Persistence of TIL infusion product at 6 
weeks following treatment, as measured 
by TCR repertoire comparison between 
the infusion product and circulating PBMC 
Evaluate the biologic 
capacity of the 
infusion product and 
association between 
persistence and 
response 
Tertiary/Exploratory  
 
 
1.  Evaluate the properties 
of the TIL culture and 
expansion including degree 
of expansion and 
immunologic phenotype of 
the infusion product. 
1. Success of primary TIL culture 
2. Degree of expansion during REP 
3. Frequency of lymphocyte 
subpopulations in the preREP and 
infusion product 
 
Data regarding the 
cell product will help 
to design future trials 
of ACT in soft tissue 
sarcoma and other 
solid tumor 
malignancies 
 
 
4 
STUDY DESIGN  
4.1 OVERALL DESIGN 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
18 
The current study will be a single-arm exploratory trial to evaluate prospectively the feasibility and 
toxicities of the TIL treatment protocol specified and the persistence of TIL survival in vivo following 
treatment. 
Survival of infused TIL will be monitored by peripheral blood samples obtained as described in the 
Schedule of Activities (Section 1.3). Up to fifteen patients will be enrolled to obtain five eligible 
patients and enrollment will be sequential. 
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN 
A phase I design was chosen since this trial represents the first experience of ACT in patients with 
advanced soft tissue sarcoma.   Patients will have vastly different prior chemotherapy regimen 
experience than patients enrolled on other ACT trials for solid tumors and therefore the safety of this 
schema is important to evaluate.   Specifically, the immune reconstitution following lymphodepletion in 
a patient population with prior cytotoxic chemotherapy treatment is a concern as patients with 
metastatic melanoma have not been typically treated in this manner.   The established immune 
reconstitution kinetics are unknown and therefore represent a concern regarding safety.   Additionally, 
nearly all patients will have received prior Adriamycin-containing regimens and therefore the cardiac 
function may be impaired.   While the function will be assessed and those with depressed function 
excluded, cardiac dysfunction would exacerbate the toxicity of IL-2. 
In addition to safety, the feasibility of this regimen is important to consider in this trial design.  Prior 
ACT trials have generally used tumor-bearing lymph nodes as the starting material from which the TIL 
product is generated.   Soft tissue sarcoma does not typically metastasize via the lymphatic system 
and therefore a recurrent tumor or metastatic deposit will be used for the starting tissue in this trial.   
Extensive prior laboratory experience has generated positive results regarding the expansion of a TIL 
product from soft tissue sarcoma after several technical manipulations from the prior melanoma 
methods.   It is important to establish the feasibility of consistently generating a TIL infusion product 
for patients with soft tissue sarcoma.    
 
4.3 JUSTIFICATION FOR DOSE 
As mentioned above, the lymphodepleting chemotherapy regimen and IL-2 infusion schedule are 
identical to the schema used in prior ACT trials at this institution and within the NCI Surgery Branch.    
The number of TIL in the final infusion product has been reported in the 1-10 billion range for prior 
ACT trials.  Preclinical laboratory experience with soft tissue sarcoma samples has shown similar 
expansion profile and therefore the expectation is that a similar number of TIL will be in the final 
infusion product.    
 
4.4 END OF STUDY DEFINITION 
A participant is considered to have completed the study if he or she has completed all phases of the 
study including the last visit or the last scheduled procedure shown in the Schedule of Activities 
(SoA), Section 1.3. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
19 
The end of the study is defined as completion of the last visit or procedure shown in the SoA in the 
trial globally. 
5 
STUDY POPULATION 
5.1 INCLUSION CRITERIA: 2-STEP DESIGN 
A 2-step design will be used to evaluate patients for eligibility: 
5.1.1 STEP 1: RESECTION OF TUMOR & INITIATION OF TIL EXPANSION 
Patients must fulfill all of the following criteria to be eligible for the study at the time of tumor resection 
and initiation of TIL expansion. 
 
1. Provision of signed and dated informed consent form 
2. Stated willingness to comply with all study procedures and availability for the duration of the 
study 
3. Male or female, aged 18 to 39 years 
4. Patients must have metastatic, high-grade soft tissue sarcoma, all subtypes will be eligible  
5. Residual measurable disease after resection of target lesion(s) for TIL growth 
6. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 to 1. ECOG 
performance status of 0 to 1 will be inferred if the patient’s level of energy is ≥ 50% of 
baseline. 
7. Patients must have progressed on at least one prior standard of care treatment 
regimen for metastatic disease. 
8. A negative pregnancy test (urine or serum) must be documented at screening for women of 
childbearing potential. 
9. A MUGA scan (ejection fraction > 50% is required) ≤ 6 months prior to lymphodepletion. 
10. Pulmonary function tests should be completed ≤ 6 months prior to lymphodepletion and forced 
expiratory volume (FEV1) > 65% or FVC > 65% of predicted are required. 
11. Adequate renal, hepatic, and hematologic function, including creatinine of ≤ 1.7 gm/dL, total 
bilirubin ≤ 2.0 mg/dL, except in patients with Gilbert’s Syndrome who must have a total 
bilirubin less than 3.0 mg/dL, AST and ALT of less than 3 X institutional upper limit of normal, 
hemoglobin of 8 gm/dL or more, white blood cells of 3000 per mm3 and total granulocytes of 
1000 per mm3 or more, and platelets of 100 000 per mm3 or more. 
12. Patients must have a positive screening EBV antibody titre on screening test. 
13. Patients that had previously grown sterile, validated TILs under good manufacturing practices 
(GMP) conditions meeting the above criteria are eligible using the previously established TIL 
product stored in the Cell Therapies Core facility for up to 2 years after harvesting. 
14. All laboratory and imaging studies must be completed and satisfactory within 30 days of 
signing the consent document. 
5.1.2 STEP 2: CHEMOTHERAPY/CELL INFUSION INCLUSION CRITERIA 
 
To be eligible for chemotherapy/cell infusion, patients must fulfil the following criteria: 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
20 
1. Patients must have adequate TILs available, as described in Appendix B. 
2. Patients of both sexes must practice birth control for 4 months after receiving the preparative 
regimen. 
3. Unless surgically sterile by bilateral tubal ligation or vasectomy of partner(s), the patient 
agrees to continue to use a method of contraception throughout the study and for 90 days 
after your last treatment such as: barrier (i.e. condom, diaphragm), hormonal, IUD, or sponge 
plus spermicide.  
4. For women who have menstruated within the past 12 months and have not had a surgical 
procedure to accomplish sterilization, pregnancy testing (urine or serum) will be performed 
within 7 days prior to treatment. 
5. Clinical performance status of ECOG 0 to 1 at the time of chemotherapy infusion. ECOG 
performance status of 0 to 1 will be inferred if the patient’s level of energy is ≥ 50% of 
baseline. 
6. Absolute neutrophil count greater than or equal to 750/mm3. 
7. Platelet count greater than or equal to 100 000/mm3. 
8. Hemoglobin greater than or equal to 8.0 g/dL. 
9. Serum ALT and AST less than 3 times the institutional upper limit of normal. 
10. Serum creatinine less than or equal to 1.7 mg/dL. 
11. Total bilirubin less than or equal to 2.0 mg/dL, except in patients with Gilbert’s Syndrome who 
must have a total bilirubin less than 3.0 mg/dL. 
12. Prothrombin time (PT) and partial thromboplastin time (PTT) within 1.5 times the institutional 
upper limit of normal 
13. Patients with echocardiogram (EKG) within 14 days of initiation of chemotherapy 
demonstrating no new rhythm, axis, or ST segment changes will be included. If new ST 
changes are present, patients may be included if cardiac stress test indicates no evidence of 
inducible cardiac ischemia. 
14. Urinalysis within 14 days demonstrating no evidence of a urinary tract infection. 
15. Patients with evidence of ongoing disease regression that is attributed to a therapy that is not 
part of the trial and that was administered after TIL harvest and expansion but prior to adoptive 
transfer of TILs should continue on prior therapy and may be treated with TIL only if their 
disease is stable or there is evidence of progressive disease. In this event as described above, 
the TIL will be frozen and stored for future use, in the event of progression, prior to the rapid 
expansion step. 
 
5.2 EXCLUSION CRITERIA 
5.2.1 EXCLUSION CRITERIA STEP 1: RESECTION OF TUMOR & INITIATION OF TIL 
EXPANSION 
Patients who meet the following criteria will be excluded from study participation: 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
21 
1. 
Patients with active systemic infections requiring intravenous antibiotics, coagulation 
disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune 
system are excluded. 
2. 
Patients that have completed a chemotherapy regimen given with the intent of 
lymphodepletion or cellular immunotherapy which included a non-myeloablative 
lymphodepletion strategy. 
3. 
Patients testing positive for HIV titer, hepatitis B surface antigen, human T-cell leukemia-
lymphoma virus (HTLV) I or II antibody, or both rapid plasma regain (RPR) and fluorescent 
treponemal antibody (FTA) are excluded.  Patients with hepatitis C antibody must have a 
negative (undetectable) viral load by polymerase chain reaction (PCR). 
4. 
Patients who are pregnant or nursing are excluded. 
5. 
Patients needing chronic immunosuppressive systemic steroids are excluded 
6. 
Patients with autoimmune diseases that require immunosuppressive medications are excluded 
7. 
Presence of a significant psychiatric disease, which in the opinion of the principal investigator 
or his designee, would prevent adequate informed consent or render immunotherapy unsafe 
or contraindicated 
8. 
Patients with central nervous system metastases will be excluded. 
9. 
Inability to comprehend and give informed consent 
 
5.3 LIFESTYLE CONSIDERATIONS 
N/A 
 
5.4 SCREEN FAILURES 
Screen failures are defined as participants who consent to participate in the clinical trial but 
do not subsequently receive the study intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants, to meet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any serious adverse event (SAE). 
Individuals who do not meet the criteria for participation in this trial (screen failure) because of 
a laboratory abnormality or pregnancy may be rescreened. Rescreened participants should 
be assigned the same participant number as for the initial screening. 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION 
Both men and women and members of all races and ethnic groups are eligible for this trial.   
It is anticipated that one patient per month will be accrued.  The source of patients will be 
from the outpatient clinics and general public.   The study will be advertised through patient 
advocacy groups, social media, and flyers in the clinic to increase participation.   Given the 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
22 
participation over one year, we will use multiple methods to contact patients including phone, 
email, and EHR patient portal to ensure continued participation. 
 
6 
STUDY INTERVENTION 
6.1 STUDY INTERVENTION(S) ADMINISTRATION 
6.1.1 STUDY INTERVENTION DESCRIPTION 
6.1.1.1 INTERLEUKIN-2 (ALDESLEUKIN, PROLEUKIN) 
Interleukin-2 (IL-2) will be provided from commercial sources via the study sponsor (Iovance). IL-2 is a 
133 amino acid long peptide primarily secreted by T-cells in response to various antigenic stimuli. The 
cytokine acts through a specific IL-2 receptor consisting of , ,  subunits. In addition to T-cell 
proliferation, IL-2 leads to activation and proliferation of natural killer (NK) cells, increasing their 
tumoricidal activity. Other actions of IL-2 include augmentation of B-cell growth and immunoglobulin 
production, enhancement of IFN-gamma and tumor necrosis factor- production from T-cells, IL-6 
production by monocytes, modulation of histamine release by basophils, and upregulation of IL-2 
receptors. This triggers the release of various other cytokines leading to the total 
immune/inflammatory reaction and resultant toxicity. 
IL-2 will be administered as an inpatient treatment within the inpatient unit that has been specially 
designed to treat patients with cellular immunotherapy and bone marrow transplants.   The physicians 
administering IL-2 and other chemotherapeutic agents described below will be appropriately 
credentialed in the delivery of these medications and management of side effects.   During the 
treatment phase (preparative chemotherapy, TIL infusion, and IL-2 dosing) the patients will be 
primarily managed by the Immune Cellular Experimental Treatment (ICE-T) service which is staffed 
by medical oncologists and physicians experienced with delivery of standard and experimental cellular 
therapies. Grade III toxicities common to IL-2 include diarrhea, nausea, vomiting, hypotension, skin 
changes, anorexia, mucositis, dysphagia, constitutional symptoms, and laboratory changes. 
Additional Grade IV and V toxicities have been seen with IL-2 (See Appendix D). 
6.1.1.2 FLUDARABINE 
Fludarabine phosphate is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9--D-
arabinofuranosyladenine (ara-A), that is relatively resistant to deamination. Fludarabine is a purine 
antagonist antimetabolite. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and 
then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate 2-fluoro-ara-
ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase, 
and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is 
not completely characterized and may be multi-faceted. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
23 
It will be purchased by the MCC pharmacy from commercial sources. Fludarabine is supplied as a 
fludarabine phosphate powder in the form of a white, lyophilized solid cake. The fludarabine powder is 
stable for at least 18 months at 2 to 8°C; when reconstituted, fludarabine is stable for at least 16 days 
at room temperature. Specialized references should be consulted for specific compatibility 
information. Fludarabine is dephosphorylated in serum, transported intracellularly, and converted to 
the nucleotide fludarabine triphosphate; this 2-fluoro-ara-ATP molecule is thought to be required for 
the drug’s cytotoxic effects. Fludarabine inhibits DNA polymerase, ribnucleotide reductase, DNA 
primase, and may interfere with chain elongation, and RNA and protein synthesis. 
Fludarabine is administered as an IV infusion in 100 mL 0.9% sodium chloride United States 
Pharmacopeia over approximately 15 to 30 minutes. At doses of 25 mg/m2/day for 5 days, the primary 
side effect is myelosuppression. However, thrombocytopenia is responsible for most cases of severe 
and life-threatening hematologic toxicities. Hemolytic anemia has been reported after 1 or more 
courses of fludarabine with or without a prior history of a positive Coomb’s test; fatal hemolytic anemia 
has been reported. In addition, bone marrow fibrosis has been observed after fludarabine therapy. 
Other common adverse effects include malaise, fatigue, anorexia, and weakness. Irreversible and 
potentially fatal central nervous system toxicity in the form of progressive encephalopathy, blindness, 
and coma is rare at the currently administered doses. More common neurologic side effects at the 
current doses of fludarabine include weakness, pain, malaise, fatigue, paresthesia, visual or hearing 
disturbances, and sleep disorders. 
Adverse respiratory effects of fludarabine include cough, dyspnea, and allergic or idiopathic interstitial 
pneumonitis. Tumor lysis syndrome has been rarely observed in fludarabine treatment of chronic 
lymphocytic leukemia (CLL). 
6.1.1.3 CYCLOPHOSPHAMIDE 
Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. It is 
biotransformed principally in the liver to active alkylating metabolites by a mixed-function microsomal 
oxidase system. These metabolites interfere with the growth of susceptible rapidly proliferating 
malignant cells. The mechanism of action is thought to involve cross-linking of tumor cell DNA. 
Cyclophosphamide is well absorbed after oral administration with a bioavailability greater than 75%. 
The unchanged drug has an elimination half-life of 3 to 12 hours. It is eliminated primarily in the form 
of metabolites, but from 5% to 25% of the dose is excreted in urine as unchanged drug. Several 
cytotoxic and noncytotoxic metabolites have been identified in urine and in plasma. Concentrations of 
metabolites reach a maximum in plasma 2 to 3 hours after an intravenous dose. Plasma protein 
binding of unchanged drug is low but some metabolites are bound to an extent greater than 60%. It 
has not been demonstrated than any single metabolite is responsible for either the therapeutic or toxic 
effects of cyclophosphamide. Although elevated levels of metabolites of cyclophosphamide have been 
observed in patients with renal failure, increased clinical toxicity in such patients has not been 
demonstrated. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
24 
Following conversion to active metabolites in the liver, cyclophosphamide functions as an alkylating 
agent and possesses potent immunosuppressive activity. The serum half- life after intravenous 
administration ranges from 3 to 12 hours; the drug and/or its metabolites can be detected in the serum 
for up to 72 hours after administration. 
Cyclophosphamide will be obtained from commercially available sources by the MCC pharmacy. It will 
be diluted in 250 mL NS and infused over approximately two hours. The dose will be based on the 
patient’s body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the 
maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables. 
Hematologic toxicity occurring with cyclophosphamide usually includes leukopenia and 
thrombocytopenia. 
Anorexia, nausea, and vomiting may occur, especially after high doses. Diarrhea, hemorrhagic colitis, 
and mucosal and oral ulceration have been reported in patients. Sterile hemorrhagic cystitis occurs in 
about 20% of patients; severity can range from microscopic hematuria to extensive cystitis with 
bladder fibrosis. Although the incidence of hemorrhagic cystitis associated with cyclophosphamide 
appears to be lower than that associated with ifosfamide, mesna (sodium 2-mercaptoethanesulfonate) 
has been used prophylactically as an uroprotective agent. 
Patients who receive high-dose cyclophosphamide may develop interstitial pulmonary fibrosis, which 
can be fatal. Hyperuricemia due to rapid cellular destruction may occur, particularly in patients with 
hematologic malignancy. Hyperuricemia may be minimized by adequate hydration, alkalinization of 
the urine, and/or administration of allopurinol. If allopurinol is administered, patients should be 
watched closely for cyclophosphamide toxicity due to allopurinol induction of hepatic microsomal 
enzymes. At high doses, cyclophosphamide can also result in a syndrome of inappropriate antidiuretic 
hormone secretion; hyponatremia with progressive weight gain without edema occurs. 
Cardiotoxicity has been observed at high doses of cyclophophamide. Deaths have occurred from 
diffuse hemorrhagic myocardial necrosis and from acute myopericarditis; in such cases, congestive 
heart failure may occur within a few days of the first dose. 
Other consequences of cyclophosphamide cardiotoxicity include arrhythmias, potentially irreversible 
cardiomyopathy, and pericarditis. Other reported adverse effects of cyclophosphamide include 
headache, dizziness, and myxedema; faintness, facial flushing, and diaphoresis. 
6.1.1.4 MESNA (SODIUM 2-MERCAPTOETHANESULFONATE, MESNUM, MESNEX, NSC-
113891) 
Mesna (sodium 2-mercaptoethanesulphonate; given by IV injection) is a synthetic sulfhydryl 
compound that can chemically interact with urotoxic metabolites of cyclophosphamide (acrolein and 4-
hydroxycyclophosphamide) to decrease the incidence and severity of hemorrhagic cystitis. 
Mesna was developed as a prophylactic agent to reduce the risk of hemorrhagic cystitis. Analogous to 
the physiological cysteine-cystine, mesna is rapidly oxidized to its major metabolite, mesna disulfide 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
25 
(dimesna). Mesna disulfide remains in the intravascular compartment and is rapidly eliminated by the 
kidneys. In the kidney, the mesna disulfide is reduced to the free thiol compound, mesna, which 
reacts chemically with the urotoxic metabolites, resulting in their detoxification. 
Mesna will be obtained commercially and is supplied as a 100 mg/mL solution. Intact ampules are 
stored at room temperature. Diluted solutions (1 to 20 mg/dL) are physically and chemically stable for 
at least 24 hours under refrigeration. Mesna is chemically stable at room temperature for 48 to 72 
hours in D5W, 48 to 72 hours in D5W/0.45% normal saline, or 24 hours in normal saline. It will be 
diluted up to 20 mg Mesna/mL fluid in D5W or normal saline and will be administered intravenously as 
a continuous infusion. Toxicities include nausea, vomiting and diarrhea. 
6.1.1.5 G-CSF (GRANULOCYTE COLONY-STIMULATING FACTOR) 
Granulocyte-colony stimulating factor (G-CSF) will be obtained commercially and is supplied in 300 
μg/mL and 480 μg/mL vials. G-CSF should be refrigerated and not allowed to freeze. The product 
bears the expiration date. It is generally stable for at least 10 months when refrigerated. The 
appropriate dose is drawn up into a syringe. G-CSF will be given daily subcutaneously as a blood 
product support if needed. The side effects of G-CSF are skin rash, myalgia and bone pain, an 
increase of preexisting inflammatory conditions, enlarged spleen with occasional associated low 
platelet counts, alopecia (with prolonged use) elevated blood chemistry levels. 
Levofloxacin (Levaquin) and Trimethoprim and Sulfamethoxazole double strength (TMP/SMX DS, 
Bactrim) 
Levaquin is used to prevent infections caused by bacteria. It is a synthetic broad spectrum 
antibacterial agent. The mechanism of action of levofloxacin involves inhibition of bacterial 
topoisomerase IV and DNA gyrase, enzymes required for DNA replication, transcription, repair, and 
recombination. An alternative antibiotic by mouth for patients who are allergic to Levaquin will be 
Keflex. 
TMP/SMX DS will be obtained by the MCC pharmacy from commercial sources. It will be used for the 
prevention of Pneumocystis carinii Pneumonia (PCP). 
The oral dose is 1 tablet orally twice a week. Like other sulfa drugs, Bactrim (sulfamethoxazole-
trimethoprim) can cause allergies, fever, nausea, and vomiting. Allergies typically develop as a 
widespread itchy red rash with fever eight to fourteen days after beginning the standard dose. 
Neutropenia, a reduction in the number of neutrophils, can also occur. 
 
6.1.1.6 ACYCLOVIR (ZOVIRAX) AND VALACYCLOVIR HYDROCHLORIDE (VALTREX) 
Acyclovir and Valtrex will be obtained by the MCC pharmacy from commercial sources. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
26 
Valtrex is the hydrochloride salt of L-valyl ester of acyclovir. It is rapidly converted to acyclovir, which 
has demonstrated antiviral activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and 
varicella-zoster virus (VZV). The inhibitory activity of acyclovir is highly selective due to its affinity for 
the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir 
into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into 
diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. 
Acyclovir triphosphate stops replication of herpes viral DNA. 
Acyclovir will be used to prevent the occurrence of herpes virus infections. It is supplied as powder for 
injection in 500 mg vials. Reconstitute in 10 mL of sterile water for injection for bacteriostatic water for 
injection to a concentration of 50 mg/mL. Reconstituted solutions should be used within 12 hours. IV 
solutions should be diluted to a concentration of 7 mg/mL or less and infused over 1 hour to avoid 
renal damage. 
Oral tablets of 200 and 800 mg are available, if the patient is able to tolerate medication by mouth. 
Reversible renal insufficiency has been reported with intravenous but not oral acyclovir. Neurologic 
toxicity including delirium, tremors, coma, acute psychiatric disturbances, and abnormal 
electroencephalography have been reported with higher doses of acyclovir. 
Should this occur, a dosage adjustment will be made or the drug should be discontinued. Stomach 
upset, headache, nausea, rash, hives, diaphoresis, hematuria; hypotension, and thrombocytosis have 
been reported. Hair loss from prolonged use has also been documented. Acyclovir will not be used 
concomitantly with other nucleoside analogs that interfere with DNA synthesis, e.g. ganciclovir. In 
renal disease, the dose is adjusted as per product labeling. 
 
6.1.1.7 FLUCONAZOLE (DIFLUCAN) 
Fluconazole will be obtained by the MCC pharmacy from commercial sources. It will be used for 
prophylaxis against fungal infections. It is available in 200 mg tablets. It can cause headache, nausea, 
vomiting, diarrhea or abdominal pain, and liver damage that may be irreversible. It can cause rashes 
and itching, which in rare cases has caused Stevens Johnson Syndrome. It has several significant 
drug interactions. The package insert should be consulted prior to prescribing. For IV administration in 
patients who cannot tolerate the oral preparation, Fluconazole comes in 2 mg/mL solution for injection 
and is prepared according to MCC pharmacy standard procedures. It should be administered at a 
maximum IV rate of 200 mg/hour. 
 
6.1.1.8 ONDANSETRON HYDROCHLORIDE (ZOFRAN) 
Ondansetron hydrochloride will be obtained by the MCC pharmacy from commercial sources. It will be 
used to control nausea and vomiting during the chemotherapy preparative regimen. It can cause 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
27 
headache, dizziness, myalgias, drowsiness, malaise, and weakness. Less common side effects 
include chest pain, hypotension, pruritis, constipation and urinary retention. Consult the package 
insert for a complete list of side effects and specific dose instructions. 
 
6.1.1.9 FUROSEMIDE (LASIX) 
Furosemide, a loop diuretic, will be obtained by the MCC pharmacy from commercial sources. It will 
be used to enhance urine output during the chemotherapy preparative regimen with 
cyclophosphamide. Adverse effects include dizziness, vertigo, paresthesias, weakness, orthostatic 
hypotension, photosensitivity, rash and pruritis. Consult the package insert for a complete list of side 
effects and specific dose instructions. 
 
6.1.1.10 
CELL PREPARATION 
The procedures and reagents for expanding the human TIL cells are contained in Appendix B. The 
cell preparation will occur in the Cell Therapy Facility at MCC (Appendix C) 
6.1.2 DOSING AND ADMINISTRATION 
Patients will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will 
be generated.  The TIL will be cultured, expanded, and tested for tumor reactivity in a state-of-the-
art GMP cell growth facility at Moffitt that is compliant with all FDA regulations regarding 
investigational cell transfer products. 
Apheresis will be performed via a 2-armed approach or via a temporary central venous catheter. 
Approximately a 7-liter exchange using a Gambro Spectra machine will be performed to generate 
cells for immune monitoring and research related testing. Specific details on the apheresis procedure 
are included in an appendix to the IND under which this trial is being conducted, BB IND 14013. 
All patients will receive non-myeloablative lymphodepleting chemotherapy with cyclophosphamide 
and fludarabine to enhance T cell persistence and effectiveness in vivo. Cyclophosphamide will be 
administered at 60 mg/kg/day I.V. in 250 mL NS over approximately 2 hours on Days –7 and –6. 
The dose will be based on the patient’s body weight, but to prevent undue toxicity, it will not exceed 
a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance 
Company, Height and Weight Table. 
 
Fludarabine will then be infused at 25 mg/m2 IVPB daily over approximately 30 minutes on Days –5 
to –1. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA) 
but will not exceed a dose calculated on surface areas based on body weights greater than 140% of 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
28 
the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight 
Tables.  
 
On day 0, all patients will receive not less than 109, and up to 1x1012 T cells in ≥250 mL NS as an 
inpatient by I.V. TIL will be infused at a rate of 5 mL/minute or less. Infusion rate will be adjusted 
downward if necessary to maintain endotoxin infusion at 5 EU/Kg/hour or less (refer to the adoptive 
cell therapy SOP and Appendix B for T cell preparation).   
 
Eight (8) to sixteen (16) hours after completing the T cell infusion, all patients will receive high dose 
interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600,000 IU/kg as an intravenous 
bolus over an approximate 15 minute period every 8-16 hours for up to 15 doses on Days 1 to 5, as 
tolerated. Doses will be skipped if patients reach Grade III or IV toxicity due to high dose IL-2, except 
for the reversible Grade III toxicities common to high dose IL-2 such as diarrhea, nausea, vomiting, 
hypotension, skin changes, anorexia, mucositis, dysphagia, or constitutional symptoms and 
laboratory changes (i.e. platelets, creatinine, total bilirubin) as detailed in Appendix C.  If the toxicity 
is easily reversed by supportive measures, then additional doses may be continued. There will be no 
dose modification for IL-2, except for morbid obesity per standard practice for the use of high dose 
IL-2. 
 
As above, doses may be skipped for hypotension or low urine output of grade III or IV that is 
controlled with neosynephrine, but IL-2 may continue if that toxicity is reversed to grade II or less 
with supportive measures. Patients will discontinue high dose IL-2 in a given cycle of treatment for 
altered mental status, supra- ventricular arrhythmias that require medication, evidence of 
myocarditis, uncontrolled hypotension, urine output less than 600 mL per 24 hours and/or creatinine 
of 3.5 gm/dL in spite of maximal supportive measures, bilirubin of 8 gm/dL, positive blood culture, or 
evidence of non-life-threatening infection. IL-2 will be permanently discontinued and not given again 
in patients who develop a life threatening ventricular arrhythmia, creatinine chronically elevated 
above 1.8 gm/dL, bilirubin that does not return to baseline, life threatening infection, myocardial 
infarction, or permanently altered mental status. 
 
 
 
Antitumor Effect – Solid Tumors 
For the purposes of this study, the baseline tumor measurements used to assess response will be 
from the Day -14 CT scan and patients should be evaluated for response at 6 weeks after TIL infusion 
then every 12 weeks.    Initial disease progression at 6 weeks requires confirmation of progression at 
12 weeks to result in patient withdrawal from study. 
6.1.3 DURATION OF THERAPY 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
29 
Response and progression will be evaluated in this study using the new international criteria proposed 
by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) (Eur J 
Ca 45:228-247, 2009). Changes in the largest diameter (unidimensional measurement) of the tumor 
lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST 1.1 
criteria. 
Definitions 
Evaluable for toxicity. All patients will be evaluable for toxicity from the time of their initiation on the 
lymphodepleting chemotherapy regimen. 
Evaluable for objective response. Only those patients who have measurable disease present at 
baseline, have received TIL infusion, and have had their disease re-evaluated will be considered 
evaluable for response. These patients will have their response classified according to the definitions 
stated below. (Note: Patients who exhibit objective disease progression prior to the 6-week post-TIL 
imaging will also be considered evaluable.) 
Evaluable Non-Target Disease Response. Patients who have lesions present at baseline that are 
evaluable but do not meet the definitions of measurable disease, have received at least one cycle of 
therapy, and have had their disease re-evaluated will be considered evaluable for non-target disease. 
The response assessment is based on the presence, absence, or unequivocal progression of the 
lesions.  
Disease Parameters 
Measurable disease. Measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) as ≥ 20 mm (≥ 2 cm) by chest x-ray or as ≥ 10 
mm (≥ 1 cm) with CT scan, MRI, or calipers by clinical examination. All tumor measurements must be 
recorded in millimeters (or decimal fractions of centimeters). 
Malignant lymph nodes. To be considered pathologically enlarged and measurable, a lymph node 
must be ≥ 15 mm (≥ 1.5 cm) in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm [0.5 cm]). At baseline and in follow-up, only the short axis 
will be measured and followed. 
Non-measurable disease. All other lesions (or sites of disease), including small lesions (longest 
diameter < 10 mm [< 1 cm] or pathological lymph nodes with ≥ 10 to < 15 mm [≥ 1 to < 1.5 cm] short 
axis), are considered non-measurable disease. Leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, are inflammatory breast disease, are considered as non-
measurable. 
Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by 
definition, simple cysts. “Cystic lesions” thought to represent cystic metastases can be considered as 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
30 
measurable lesions if they meet the definition of measurability described above. However, if non-
cystic lesions are present in the same patient, these are preferred for selection as target lesions. 
Target lesions. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all involved organs, but in addition should be those that lend 
themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest 
lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion 
that can be measured reproducibly should be selected. A sum of the diameters (longest for non-nodal 
lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the 
baseline sum diameters. If lymph nodes are to be included in the sum, then only the short axis is 
added into the sum. The baseline sum diameters will be used as reference to further characterize any 
objective tumor regression in the measurable dimension of the disease. 
Non-target lesions. All other lesions (or sites of disease) including any measurable lesions over and 
above the 5 target lesions should be identified as non-target lesions and should also be recorded at 
baseline. Measurements of these lesions are not required, but the presence, absence, or in rare 
cases unequivocal progression of each should be noted throughout follow-up. 
Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment. 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is preferred 
to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged but are 
assessable by clinical exam. 
Clinical lesions. Clinical lesions will only be considered measurable when they are superficial (e.g., 
skin nodules and palpable lymph nodes) and ≥ 10 mm (≥ 1 cm) diameter as assessed using calipers 
(e.g., skin nodules). In the case of skin lesions, documentation by color photography, including a ruler 
to estimate the size of the lesion, is recommended. 
Chest radiography. Lesions on chest x-ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by aerated lung. However, CT is preferable. 
Conventional CT and MRI. This guideline has defined measurability of lesions on CT scan based on 
the assumption that CT slice thickness is 5 mm (0.5 cm) or less. If CT scans have slice thickness 
greater than 5 mm (0.5 cm), the minimum size for a measurable lesion should be twice the slice 
thickness.  


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
31 
Use of MRI remains a complex issue. MRI has excellent contrast and spatial and temporal resolution; 
however, there are many image acquisition variables involved in MRI that greatly impact image 
quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI is variable globally. 
As with CT, if an MRI is performed, the technical specifications of the scanning sequences used 
should be optimized for the evaluation of the type and site of disease. Furthermore, as with CT, the 
modality used at follow-up should be the same as that used at baseline, and the lesions should be 
measured/assessed on the same pulse sequence. It is beyond the scope of the RECIST guidelines to 
prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseases. Ideally, 
the same type of scanner should be used and the image acquisition protocol should be followed as 
closely as possible to prior scans. Body scans should be performed with breath-hold scanning 
techniques, if possible. 
PET-CT. At present, the low dose or attenuation correction CT portion of a combined PET-CT is not 
always of optimal diagnostic CT quality for use with RECIST measurements. However, if the reading 
radiologist can document that the CT performed as part of a PET-CT is of identical diagnostic quality 
to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be used for 
RECIST measurements and can be used interchangeably with conventional CT in accurately 
measuring cancer lesions over time. Note, however, that the PET portion of the CT introduces 
additional data that may bias an investigator if it is not routinely or serially performed. 
Ultrasonography. Ultrasonography is not useful in assessment of lesion size and should not be used 
as a method of measurement. Ultrasonographic examinations cannot be reproduced in their entirety 
for independent review at a later date, and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to the 
next. If new lesions are identified by ultrasonography in the course of the study, confirmation by CT or 
MRI is required. If there is concern about radiation exposure at CT, MRI may be used instead of CT in 
selected instances. 
Endoscopy and Laparoscopy. The utilization of these techniques for objective tumor evaluation is not 
advised. However, such techniques may be useful to confirm complete pathological response when 
biopsies are obtained or to determine relapse in trials where recurrence following complete response 
(CR) or surgical resection is an endpoint. 
Cytology and Histology. Gross and histological examination of the formalin-fixed and paraffin-
embedded tissue following the standard sarcoma pathology protocol at Moffitt Cancer Center can be 
used to differentiate between partial responses (PR) and complete responses (CR) in rare cases 
(e.g., residual lesions in tumor types where known residual benign tumors can remain). 
The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during 
treatment when the measurable tumor has met criteria for response or stable disease is mandatory to 
differentiate between response or stable disease (an effusion may be a side effect of the treatment) 
and progressive disease. 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
32 
Response Criteria 
Evaluation of Target Lesions 
• 
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 mm (< 1 cm). 
• 
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, 
taking as reference the baseline sum diameters. 
• 
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is 
the smallest on study). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm (0.5 cm). (Note: the appearance of one or 
more new lesions is also considered progression). 
• 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study. 
Evaluation of Non-Target Lesions 
• 
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor 
marker level. All lymph nodes must be non-pathological in size (< 10 mm [< 1 cm] short axis). 
o Note: If tumor markers are initially above the upper normal limit, they must normalize 
for a patient to be considered in complete clinical response. 
• 
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of 
tumor marker level above the normal limits. 
• 
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions. Unequivocal progression should not normally trump 
target lesion status. It must be representative of overall disease status change, not a single 
lesion increase. 
• 
Although a clear progression of “non-target” lesions only is exceptional, the opinion of the 
treating physician should prevail in such circumstances, and the progression status should be 
confirmed at a later time by the review panel (or Principal Investigator). 
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the lymphodepleting 
chemotherapy until disease progression/recurrence (taking as reference for progressive disease the 
smallest measurements recorded since the treatment started). The patient's best response 
assignment will depend on the achievement of both measurement and confirmation criteria.  See table 
for further clarification. 
 
Target Lesions 
Non-Target 
Lesions 
New Lesions 
Overall 
Response 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
33 
 
 
 
 
 
 
 
 
 
 
 
Duration of Response 
Duration of overall response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR until 
the first date that progressive disease is objectively documented. 
Duration of stable disease: Stable disease is measured from the start of lymphodepleting 
chemotherapy until the criteria for progression are met, taking as reference the smallest 
measurements recorded since the treatment started, including the baseline measurements. 
Progression-Free Survival:  PFS is defined as the duration of time from start of lymphodepleting 
chemotherapy to time of progression or death, whichever occurs first. 
 
6.2 PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY 
 
6.2.1 ACQUISITION AND ACCOUNTABILITY 
CR 
CR 
No 
CR 
CR 
Non-CR/Non-PD 
No 
PR 
PR 
Non-PD 
No 
PR 
SD 
Non-PD 
No 
SD 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
34 
All medications used will be provided by the pharmacy.  The TIL infusion product will be 
prepared according to the SOP developed and retained in the Cell Therapy Facility, 
described in Appendix B.    
 
6.2.2 FORMULATION, APPEARANCE, PACKAGING, AND LABELING 
The formulation and packaging will be according to the SOP developed and retained in the 
Cell Therapy Facility. 
 
6.2.3 PRODUCT STORAGE AND STABILITY 
Medications will be stored consistent with the package insert provided by the manufacturer.  
The TIL infusion product will be kept at 4oC during transfer from the Cell Therapy Facility 
following collection on Day 0 and brought to room temperature immediately prior to infusion. 
 
6.2.4 PREPARATION 
See Appendix B 
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING 
This is a non-blinded study and there is no randomization of treatment for the enrolled patients.   
Response will be assessed by an independent radiologist using criteria described in section 6.1.3. 
 
6.4 STUDY INTERVENTION COMPLIANCE 
For the purposes of this study at Moffitt Cancer Center, the Protocol Data Management System 
(OnCore) will be employed.  All patients will be registered in OnCore before any study specific tests are 
performed.  
This trial will be monitored continuously by the principal investigator who will be assisted by the assigned 
clinical trial coordinator.  
To ensure adherence to the protocol, safety and monitoring reports will be submitted to the Moffitt 
Internal Protocol Data Safety Monitoring Committee (PDSMC) once two patients have been treated or 
once the early stopping rule threshold has been met (whichever comes first) or more frequently if 
requested by the PDSMC. A final safety and monitoring report will be submitted to the PDSMC within 3 
months of the last subject having been enrolled.  


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
35 
Internal audits will be conducted by Moffitt regulatory personnel in accordance with applicable regulatory 
standards. The following elements will be reviewed: 
1. Source documentation verification of eligibility and protocol compliance 
2. Regulatory review of IRB compliance and external reporting requirements 
3. Drug/device accountability and handling 
4. Completeness and quality of data 
 
6.5 CONCOMITANT THERAPY 
 N/A 
 
6.5.1 RESCUE MEDICINE 
N/A 
7 
STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
 
7.1 DISCONTINUATION OF STUDY INTERVENTION 
There are only two phases of treatment which are continuous: the lymphodepleting chemotherapy 
phase and the post-TIL infusion IL-2 phase.   Criteria for discontinuation of both are listed below. 
Lymphodepleting Chemotherapy Phase 
Patients that develop an acute bacterial or viral infection during the lymphopenic phase of treatment 
will not continue to receive further treatments (TIL infusion and/or IL-2 infusion).   Treatment may 
resume when deemed safe upon resolution of the infection.  Patients who experience any Grade 4 
non-hematologic organ-specific adverse event (neurologic, pulmonary, cardiac, gastrointestinal, 
genitourinary, hepatic or dermatologic) that does not resolve prior to TIL infusion will not receive TIL 
infusion and subsequent IL-2 infusion. 
Post-TIL Infusion IL-2 Phase 
Patients who experience any Grade 4 non-hematologic organ-specific adverse event (neurologic, 
pulmonary, cardiac, gastrointestinal, genitourinary, hepatic or dermatologic) not felt due to sarcoma 
or a pre-existing condition will discontinue further IL-2 administration. Patients who develop a life-
threatening Grade IV toxicity due to administration of high dose IL-2 such as: ventricular arrhythmia, 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
36 
life threatening infection, myocardial infarction, or permanently altered mental status will have IL-2 
permanently discontinued.   
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY 
Participants are free to withdraw from participation in the study at any time upon request. 
An investigator may discontinue or withdraw a participant from the study for the following reasons: 
• Pregnancy 
• Significant study intervention non-compliance  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the study would not be in the best 
interest of the participant 
• Disease progression which requires discontinuation of the study intervention 
• If the participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation 
The reason for participant discontinuation or withdrawal from the study will be recorded within the 
patient’s medical record and OnCore and/or the Clinical Trial Management System (CTMS). Subjects 
who sign the informed consent form and are randomized but do not receive the study intervention 
may be replaced. Subjects who sign the informed consent form, and are randomized and receive the 
study intervention, and subsequently withdraw, or are withdrawn or discontinued from the study, may 
be replaced. 
 
7.3 LOST TO FOLLOW-UP 
A participant will be considered lost to follow-up if he or she fails to return for 2 consecutive scheduled 
visits and is unable to be contacted by the study site staff.  
The following actions must be taken if a participant fails to return to the clinic for a required study visit: 
• 
The site will attempt to contact the participant and reschedule the missed visit within 3 
business days and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain if the participant wishes to and/or should continue in the study. 
• 
Before a participant is deemed lost to follow-up, the investigator or designee will make every 
effort to regain contact with the participant (where possible, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing address or local equivalent 
methods). These contact attempts should be documented in the participant’s medical record or 
study file.  


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
37 
• 
Should the participant continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up. 
 
8 
STUDY ASSESSMENTS AND PROCEDURES 
 
8.1 SAFETY ASSESSMENTS  
Safety assessments will be performed at time points according to the study calendar (section 1.3).  
Additionally, as stated above, there will be a separate assessment for eligibility prior to 
lymphodepleting chemotherapy. 
8.1.1 TREATMENT – CHEMOTHERAPY/CELL INFUSION 
Patients must fulfill all of the following criteria to be eligible. Laboratory testing must be complete and 
satisfactory within 14 days of initiation of chemotherapy. Imaging tests must be complete and 
satisfactory within 28 days of initiation of chemotherapy, and the identical criteria and management 
will be followed as discussed in sections 5.1.1 and 5.1.2. 
 
Apheresis will be performed on all patients 
a. Patients will be evaluated by a physician or advanced practice provider (advanced 
registered nurse practitioner or physician’s assistant) for clearance and certification 
prior to the initiation of the apheresis regimen. Any measurable disease found on 
physical examination will be documented within 30 days prior to initiation of 
chemotherapy. However, if there are no measurable metastatic lesions present, then 
no physical measurements will be documented. 
b. Complete blood count, differential, chemistry panel including liver functions, mineral, 
kidney, and electrolytes, PT/PTT, platelet count, type and screen, LDH, Free T4, TSH, 
urine or serum β-HCG pregnancy test (for women of child-bearing potential), EKG, and 
chest x-ray will be performed within 14 days before the apheresis. 
 
8.1.2 TREATMENT PLAN 
Patients will undergo tumor resection from which the tumor infiltrating lymphocyte (TIL) product will be 
generated. The TIL will be cultured, expanded, and tested for tumor reactivity in a state-of-the-art 
GMP cell growth facility at MCC that is compliant with all FDA regulations regarding investigational 
cell transfer products. 
Apheresis will be performed via a 2-armed approach or via a temporary central venous catheter. 
Approximately a 7-liter exchange using a Gambro Spectra machine will be performed to generate 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
38 
cells for immune monitoring and research-related testing. Specific details on the apheresis procedure 
are included in an appendix to the IND under which this trial is being conducted, BB IND -18646. 
All patients will receive nonmyeloablative lymphodepleting chemotherapy with cyclophosphamide and 
fludarabine to enhance T-cell persistence and effectiveness in vivo. Cyclophosphamide will be 
administered at 60 mg/kg/day IV in 250 mL NS over approximately 2 hours on Days -7 and -6. The 
dose will be based on the patient’s bodyweight, but to prevent undue toxicity, it will not exceed a dose 
greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company 
Height and Weight Table. 
Fludarabine will then be infused at 25 mg/m2 IVPB daily over approximately 30 minutes on Days –5 to 
–1. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA) but 
will not exceed a dose calculated on surface areas based on body weights greater than 140% of the 
maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.  
On day 0, all patients will receive not less than 109, and up to 1x1012 T cells in ≥250 mL NS as an 
inpatient by IV. TILs will be infused at a rate of 5 mL/minute or less. Infusion rate will be adjusted 
downward if necessary to maintain endotoxin infusion at 5 EU/Kg/hour or less (refer to the adoptive 
cell therapy SOP and Appendix B for T cell preparation). 
Eight (8) to sixteen (16) hours after completing the T cell infusion, all patients will receive high-dose 
interleukin-2 (IL-2) on an inpatient basis at the standard dose of 600 000 IU/kg as an intravenous 
bolus over an approximate 15-minute period every 8 to 16 hours for up to 15 doses on days 1 to 5, as 
tolerated. Doses will be skipped if patients reach grade III or IV toxicity due to high-dose IL-2, except 
for the reversible grade III toxicities common to high-dose IL-2, such as diarrhea, nausea, vomiting, 
hypotension, skin changes, anorexia, mucositis, dysphagia, or constitutional symptoms and laboratory 
changes (i.e. platelets, creatinine, total bilirubin) as detailed in Appendix D. If the toxicity is easily 
reversed by supportive measures, then additional doses may be continued. There will be no dose 
modification for IL-2, except for morbid obesity per standard practice for the use of high-dose IL-2. 
As above, doses may be skipped for hypotension or low urine output of grade III or IV that is 
controlled with neosynephrine, but IL-2 may continue if that toxicity is reversed to grade II or less with 
supportive measures. Patients will discontinue high-dose IL-2 in a given cycle of treatment for altered 
mental status, supraventricular arrhythmias that require medication, evidence of myocarditis, 
uncontrolled hypotension, urine output less than 600 mL per 24 hours, and/or creatinine of 3.5 gm/dL 
in spite of maximal supportive measures, bilirubin of 8 gm/dL, positive blood culture, or evidence of 
non–life-threatening infection. IL-2 will be permanently discontinued and not given again to patients 
who develop a life-threatening ventricular arrhythmia, creatinine chronically elevated above 1.8 
gm/dL, bilirubin that does not return to baseline, life-threatening infection, myocardial infarction, or 
permanently altered mental status. 
The phase of treatment including the non-myeloablative chemotherapy, TIL infusion, and IL-2 dosing 
present risk to the patient in terms of toxicity with the side effects of chemotherapy and IL-2 being the 
most prominent.  For this reason, these portions of treatment will be administered as inpatient 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
39 
treatment within the inpatient unit that has been specially designed to treat patients with cellular 
immunotherapy and bone marrow transplants.   The physicians prescribing IL-2 and other 
chemotherapeutic agents will be appropriately credentialed in the delivery of these medications and 
management of side effects.   During the treatment phase (preparative chemotherapy, TIL infusion, 
and IL-2 dosing) the patients will be primarily managed by the Immune Cellular Experimental 
Treatment (ICE-T) service which is staffed by medical oncologists and physicians experienced with 
delivery of standard and experimental cellular therapies. 
For the evaluation of peripheral blood cells following T-cell transfer, 60 mL blood samples in cell 
preparation or heparin tubes will be obtained on Days -28, 7, 14, 21, 28, 35, 84 , 168, 252, 336, and 
420, when feasible. A 10 mL blood sample will be collected on Day 0. This is in addition to apheresis 
that will be performed prior to lymphodepletion and at week 6.These time points were selected based 
on previous studies at the National Cancer Institute. During high dose IL-2 administration (days 1-5), 
peripheral blood mononuclear cell (PBMC) yields are low; therefore, day 7 has been selected as the 
earliest feasible time point to obtain cells and evaluate the immediate effects of immunization. The 
other days have been selected as later time points to evaluate T-cell persistence and function. Sera 
samples will be obtained from the apheresis sample prestudy and week 6. Prophylaxis Treatment 
Infection Prevention and Pneumocystis carinii Pneumonia (PCP) Prophylaxis 
Patients will receive Levaquin at 500 mg daily (or Keflex at 500 mg 3 times a day if allergic to 
Levaquin) until absolute neutrophil count recovers to greater than 500/mm3 and the fixed combination 
of trimethoprim (TMP) and sulfamethoxazole (SMX) as double strength (DS) tablet [DS tabs = TMP 
160 mg/tab and SMX 800 mg/tab ] 1 orally twice a week. TMP/SMX-DS will be taken by patients 
beginning on Day -7 and continuing for a minimum of 6 months post chemotherapy and until CD4 
counts are > 200 cells/mm3 on 2 consecutive follow-up lab studies. Patients with sulfa allergies will 
receive aerosolized pentamidine 300 mg per nebulizer within 1 week prior to admission and continued 
monthly until absolute neutrophil count is greater than 1000/uL. 
Patients will be given antibiotics (Levaquin or Ceftazidine if allergic to Levaquin) IV during high-dose 
IL-2 therapy. 
Herpes Virus Prophylaxis 
At the time of the T-cell infusion, patients with positive HSV serology will be administered valcyclovir 
500 mg orally daily if patient is able to take oral medications or acyclovir 5 mg/kg IV piggyback every 8 
hours if patient needs intravenous medications, which will be continued until absolute neutrophil count 
is greater than 1000/uL. Reversible renal insufficiency has been reported with IV-administered 
acyclovir but not with oral acyclovir. Neurologic toxicity including delirium, tremors, coma, acute 
psychiatric disturbances, and abnormal electroencephalography have been reported with higher 
doses of acyclovir. If symptoms occur, a dosage adjustment will be made or the drug will be 
discontinued. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
40 
Acyclovir will not be used concomitantly with other nucleoside analogs (e.g. ganciclovir), which 
interfere with DNA synthesis. In patients with renal disease, the dose is adjusted as per product 
labeling. 
Fungal Prophylaxis 
Patients will begin Fluconazole 200 mg orally daily with the T-cell infusion (Day 0) and continue until 
the absolute neutrophil count is > 1000/uL. 
Empiric Antibiotics 
Patients will start on broad-spectrum antibiotics, either a 3rd or 4th generation cephalsosporin or a 
quinolone for fevers  38.5oC with an absolute neutrophil count less than 500/mm3. Aminoglycosides 
should be avoided unless there is clear evidence of sepsis. Infectious disease consultation will be 
obtained from all patients with unexplained fever or any infectious complications. 
Blood Product Support 
In order to reduce neutropenia following chemotherapy and T-cell infusion, G-CSF will be given, 
starting Day +1 (>24hours from TIL infusion) at 5 μg/kg/day daily subcutaneously until neutrophil 
counts reach >1.5 K/uL. The patient will also receive platelets and packed red blood cells (PRBC’s) as 
needed, using daily complete blood counts as a guide. Attempts will be made to keep Hb > 7.0 gm/dL 
and platelets > 20 000/uL. Leukocyte filters will be used for all blood and platelet transfusions to 
decrease sensitization to transfused white blood cells and decrease the risk of cytomegalovirus 
infection. Irradiated blood and blood products should be used. 
8.1.3 EVALUATION DURING STUDY 
During the preparative regimen patients will have a complete blood count and comprehensive 
metabolic panel every day of treatment.  During the IL-2 phase of treatment, patients will have a 
complete blood count and comprehensive metabolic panel prior to each infusion (8 hour intervals). 
Patients will be monitored with vital signs at baseline and after cell infusion per inpatient unit protocol. 
Phlebotomy will be performed prior to tumor harvest and/or excision on Day -28, lymphodepletion (as 
part of apheresis) on Day -14, and again on Days 0, 7, 14, 21, 28, 35, 42 (as a part of apheresis), 84 
,168, 252, 336, and 420 when feasible. These blood samples will be used to evaluate T-cell 
persistence and function.  
Complete evaluation of evaluable lesions with physical examination and appropriate CT scans will be 
performed at approximately 6 weeks (+/- 7 days) and at 12 weeks (+/- 7 days) after the cell infusion, 
at which time patients will be restaged. 
Follow-up visits with CT scans to evaluate disease will then be then be conducted every 3 months (+/- 
14 days) for 12 months or until disease progression, withdrawal of consent, loss to follow-up, or death, 
whichever occurs first. After confirmed disease progression subjects will be followed every 3 months 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
41 
for overall survival and report of any subsequent anticancer treatments. This can be accomplished by 
visit or phone contact. 
Excess blood and tissue specimens collected in the course of this research project may be banked 
and provided in the future to investigators with MCC IRB-approved research protocols. 
 
8.1.4 RETREATMENT 
Patients will not be eligible for retreatment on this study. 
 
8.2 OTHER ASSESSMENTS 
 
 
8.3 BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES OR OTHER ENDPOINTS 
Phlebotomy will be performed prior to tumor harvest and/or excision on Day -28, lymphodepletion (as 
part of apheresis) on Day -14, and again on Days 0, 7, 14, 21, 28, 35, 42 (as a part of apheresis), 84 
,168, 252, 336, and 420 when feasible. These blood samples will be used to evaluate T-cell 
persistence and function. The PBMC will be isolated from these samples and flow cytometry will be 
used to assess the phenotypic distribution of immune cell subpopulations.   The TCR repertoire of the 
infusion product and PBMC at each time point will be assessed to evaluate the persistence of the 
infusion product. 
 
8.4 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS 
 
8.4.1 DEFINITION OF ADVERSE EVENTS (AE) 
Adverse event means any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention-related (21 CFR 312.32 (a)). 
8.4.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
An adverse event or suspected adverse reaction is considered "serious" if, in the view of the 
investigator or treating physician, it results in any of the following outcomes:  
• 
death,  
• 
a life-threatening adverse event,  
• 
inpatient hospitalization or prolongation of existing hospitalization,  


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
42 
• 
a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
• 
a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life-threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency or drug abuse. 
 
8.4.3 CLASSIFICATION OF AN ADVERSE EVENT 
 
8.4.3.1 SEVERITY OF EVENT 
 
All AEs will be graded using the CTCAE 5.0 criteria.  
For AEs not included in the protocol-defined grading system (grade 1 to 4), the following guidelines 
will be used to describe severity. 
 
• 
Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• 
Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning. 
• 
Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life-threatening or 
incapacitating. Of note, the term “severe” does not necessarily equate to “serious”.] 
8.4.3.2 RELATIONSHIP TO STUDY INTERVENTION 
 
For all collected AEs, the PI will determine the AE’s causality based on temporal relationship and 
his/her clinical judgment. The degree of certainty about causality will be graded using the categories 
shown below. 
Definitely Related – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, 
occurs in a plausible time relationship to drug administration and cannot be explained by concurrent 
disease or other drugs or chemicals. The response to withdrawal of the drug (dechallenge) should be 
clinically plausible. The event must be pharmacologically or phenomenologically definitive, with use of 
a satisfactory rechallenge procedure if necessary. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
43 
Probably Related – There is evidence to suggest a causal relationship, and the influence of other 
factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a 
reasonable time after administration of the drug, is unlikely to be attributed to concurrent disease or 
other drugs or chemicals, and follows a clinically reasonable response on withdrawal (dechallenge). 
Rechallenge information is not required to fulfill this definition. 
Possibly Related – There is some evidence to suggest a causal relationship (eg, the event occurred 
within a reasonable time after administration of the trial medication). However, other factors may have 
contributed to the event (eg, the participant’s clinical condition, other concomitant events). Although 
an AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more 
information and later be upgraded to “probably related” or “definitely related,” as appropriate. 
Unlikely to be related – A clinical event, including an abnormal laboratory test result, whose temporal 
relationship to drug administration makes a causal relationship improbable (eg, the event did not 
occur within a reasonable time after administration of the trial medication) and in which other drugs or 
chemicals or underlying disease provides plausible explanations (eg, the participant’s clinical 
condition, other concomitant treatments). 
Not Related – The AE is completely independent of study drug administration, and/or evidence exists 
that the event is definitely related to another etiology. There must be an alternative, definitive etiology 
documented by the PI. 
 
All adverse events will be recorded according to this table: 
 
Attribution 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
Not related 
X 
X 
X 
Unlikely 
X 
X 
X 
Possibly 
X 
X 
X 
X 
X 
Probably 
X 
X 
X 
X 
X 
Definitely 
X 
X 
X 
X 
X 
Exceptions to this rule will include events and laboratory abnormalities that represent common 
symptoms and abnormalities of sarcoma and chemotherapy and/or have no clinical significance: 
 
• 
Abnormalities in hematologic parameters due to myelosuppressive therapeutic effect: 
 
i. 
Anemia, neutropenia, lymphopenia, thrombocytopenia 
ii. 
Epistaxis or bleeding except for catastrophic CNS or pulmonary 
hemorrhage 
 
• 
Common symptoms of cancer (unless grade ≥ 3) including: 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
44 
 
i. 
Fatigue 
ii. 
Weakness 
iii. 
Bone, joint or muscle pain 
iv. 
Alopecia 
v. 
Loss of appetite, nausea, vomiting 
vi. 
Chemistry abnormalities (phosphorus, calcium, glucose) 
vii. 
Coagulation abnormalities (shortened PT, PTT, increased fibrinogen) 
 
• 
Laboratory abnormalities: 
 
i. 
LDH (increased or decreased) 
ii. 
Alkaline phosphatase (increased or decreased) 
iii. 
Low levels of the following: AST, ALT, creatinine, BUN, uric acid, bilirubin, albumin, 
total protein 
iv. 
Electrolyte abnormalities (sodium, potassium, bicarbonate, CO2, 
magnesium 
 
• 
General therapy related events 
 
i. 
Catheter related events 
ii. 
Rash related to antibiotic use 
 
8.4.3.3 EXPECTEDNESS  
The PI will be responsible for determining whether an AE is expected or unexpected. An AE will be 
considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk 
information previously described for the study agent. 
8.4.4 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP 
 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention 
of study personnel during study visits and interviews of a study participant presenting for medical 
care, or upon review by a study monitor. 
 
Adverse events can be spontaneously reported or elicited during open-ended questioning, 
examination, or evaluation of a patient. 
 
All AEs, including local and systemic reactions not meeting the criteria for SAEs, will be captured on 
the appropriate case report form (CRF). Information to be collected will include event description, time 
of onset, clinician’s assessment of severity, relationship to study product (assessed only by those with 
the training and authority to make a diagnosis), and time of resolution/stabilization of the event. All 
AEs occurring while on study must be documented appropriately regardless of relationship. All AEs 
will be followed to adequate resolution. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
45 
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any 
time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the 
event at each level of severity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each episode. 
 
All events beginning with the TIL Harvest (Day -28) until each patient is discharged from the hospital 
following the initial IL-2 infusion will be reported. At each study visit, the investigator will inquire about 
the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until 
resolution or stabilization. 
 
8.4.5 ADVERSE EVENT REPORTING  
All adverse events will be monitored and documented using adverse event case report 
forms/worksheets beginning at day  -28 (TIL Harvest) and continuing until each patient is 
discharged from the hospital following the initial IL-2 infusion. On-going adverse events will 
be followed for 84 days after TIL infusion or until progression, loss to follow-up, withdrawal of 
consent, death, or initiation of new cancer treatment. 
8.4.6 SERIOUS ADVERSE EVENT REPORTING  
 
The PI will immediately report to the sponsor any serious adverse event, whether or not considered 
study intervention related, including those listed in the protocol or investigator brochure and must 
include an assessment of whether there is a reasonable possibility that the study intervention caused 
the event. Study endpoints that are serious adverse events (e.g., all-cause mortality) must be reported 
in accordance with the protocol unless there is evidence suggesting a causal relationship between the 
study intervention and the event (e.g., death from anaphylaxis). In that case, the investigator must 
immediately report the event to the sponsor. 
All serious adverse events (SAEs) will be followed until satisfactory resolution or until the site 
investigator deems the event to be chronic or the participant is stable. Other supporting 
documentation of the event may be requested by the Data Coordinating Center (DCC)/study sponsor 
and should be provided as soon as possible. 
It is the responsibility of the PI and the research team to ensure that serious adverse events are 
reported according to the Code of Federal Regulations, Good Clinical Practices, the protocol 
guidelines, the sponsor’s guidelines, and Institutional Review Board policy. 
All adverse experience reports must include the patient number, age, sex, weight, severity of reaction 
(mild, moderate, severe), relationship to study drug (probably related, unknown relationship, definitely 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
46 
not related), date and time of administration of test medications, all concomitant medications, and 
medical treatment provided. The PI is responsible for evaluating all adverse events to determine 
whether criteria for “serious” as defined above are present. Adverse drug reactions that are serious, 
unlisted/unexpected, and at least possibly associated to the drug, and that have not previously been 
reported in the Investigator’s Brochure, or reference safety information document should be reported 
promptly to the Food and Drug Administration (FDA) in writing by each investigator/physician engaged 
in clinical research. A clear description of the suspected reaction should be provided along with an 
assessment as to whether the event is drug or disease related.  
The Principal Investigator or designee shall notify the FDA by telephone or by fax of any unexpected 
fatal or life threatening experience associated with the use of the drug, as soon as possible, but no 
later than 7 calendar days after the sponsor’s initial receipt of the information. Each phone call or fax 
shall be transmitted to the FDA new drug review division in the Center for Drug Evaluation and 
Research or the product review division in the Center for Biologics Evaluation and Research that has 
responsibility for review of the IND if applicable. 
The Principal Investigator is required to notify his Institutional Review Board (IRB) of a serious 
adverse event according to institutional policy. 
Expedited reporting to the FDA on a MEDWatch 3500A form will be used for all unexpected serious 
adverse events as defined in 21 CFR 312/32, for all non- hematologic Grade IV-V organ adverse 
events, for all grades 3-5 infusion reactions attributed to TIL, and for all grades 3-5 autoimmune 
events. TIL infusion reactions will be readily identified as there is an 8-16 hour window between TIL 
infusion and initiation of high dose IL-2. 
In the annual report to the FDA, we plan to list infusion reactions and autoimmune events separately. 
In addition, all grade 3-5 toxicities not deemed due to the sarcoma or preexisting disorders will be 
added to the summary reports 
 
8.4.7 REPORTING EVENTS TO PARTICIPANTS  
N/A 
 
8.4.8 EVENTS OF SPECIAL INTEREST  
The use of the nonmyeloablative regimen in this protocol is a major procedure which entails serious 
discomforts and hazards for the patient. Although it is anticipated that this protocol is relatively safe 
because of the expected recovery of the patients’ bone marrow within 2 to 4 weeks, fatal 
complications are possible. It is therefore only appropriate to carry out this experimental procedure in 
the context of life threatening metastatic cancer. The major hazards are infection and disease 
progression. The major discomforts are nausea, mucositis, anorexia, diarrhea, fever and malaise. 
Side effects of common drugs used in this nonmyeloablative regimen include: 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
47 
Cyclophosphamide: Marrow suppression, nausea, mucositis, rash, hemorrhagic cystitis, myocardial 
damage, alopecia, infertility, nausea and vomiting, syndrome of inappropriate antidiuretic hormone 
secretion. 
Fludarabine: Myelosuppression, fever and chills, nausea and vomiting, malaise, fatigue, anorexia, 
weakness, neurologic toxicity, and interstitial pneumonitis. Serious opportunistic infections have 
occurred in CLL patients treated with fludarabine. 
Antimicrobials in general: Allergic reactions, renal impairment, nausea, vomiting, hepatic 
damage, marrow suppression. 
High-Dose IL-2: A variety of side effects have been associated with high-dose IL-2 administration in 
our experience at the NCI and a listing of these side effects in 652 patients who received 1,039 
treatment courses are listed in Appendix D. 
Adoptive cell therapy with TIL: a variety of side effects that potentially overlap with high-dose IL2 
have been associated with adoptive cell therapy in our experience and at the NCI. Prominent 
long-term side effects include: vitiligo, high frequency hearing loss, anemia and uveitis. 
 
8.4.9 REPORTING OF PREGNANCY  
 
Pregnancy, although not itself a serious adverse event, should also be reported on a serious adverse 
event form or pregnancy form and be followed up to determine outcome, including spontaneous or 
voluntary termination, details of birth, and the presence or absence of any birth defects or congenital 
abnormalities. 
 
8.5 UNANTICIPATED PROBLEMS 
 
8.5.1 DEFINITION OF UNANTICIPATED PROBLEMS (UP) 
 
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks 
to participants or others to include, in general, any incident, experience, or outcome that meets all of 
the following criteria: 
 
• 
Unexpected in terms of nature, severity, or frequency given (a) the research procedures that 
are described in the protocol-related documents, such as the Institutional Review Board (IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the 
participant population being studied; 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
48 
• 
Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and 
• 
Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized. 
 
8.5.2  UNANTICIPATED PROBLEM REPORTING  
 
The investigator will report unanticipated problems (UPs) to the reviewing Institutional Review Board 
(IRB) and to the Data Coordinating Center (DCC)/lead principal investigator (PI). The UP report will 
include the following information: 
• 
Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number; 
• 
A detailed description of the event, incident, experience, or outcome;  
• 
An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• 
A description of any changes to the protocol or other corrective actions that have been taken 
or are proposed in response to the UP. 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
• 
UPs that are serious adverse events (SAEs) will be reported to the IRB, depending on their 
policy, and to the DCC/study sponsor within 2 business days of the investigator becoming 
aware of the event.  
• 
Any other UP will be reported to the IRB and to the DCC/study sponsor within 4 business days 
of the investigator becoming aware of the problem.  
• 
All UPs should be reported to appropriate institutional officials (as required by an institution’s 
written reporting procedures), the supporting agency head (or designee), and the Office for 
Human Research Protections (OHRP) within 2 business days of the IRB’s receipt of the report 
of the problem from the investigator. 
 
8.5.3 REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS  
N/A 
 
9 
STATISTICAL CONSIDERATIONS  
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
49 
9.1 STATISTICAL HYPOTHESES 
 
Feasibility is the primary endpoint of this trial, which is defined as a patient who can complete trial 
related therapy. If it is feasible for at least 3 patients out of 5 eligible patients, then this will be 
considered successful.  Upon successful completion, a larger trial with efficacy endpoints will be 
designed.   As the completion of treatment requires successful growth and expansion of T-cells, we 
will track causes of production failure to improve methods in the ultimate design of a trial with efficacy 
endpoints. 
9.2 SAMPLE SIZE DETERMINATION 
 
As this is a phase I design with safety/feasibility as the endpoint, there are no sample size calculations 
applicable.   The sample size of 5 patients was chosen as a number that would yield sufficient safety 
data and opportunity to identify any possible efficacy signal from which to design a subsequent phase 
2 trial.    
 
9.3 POPULATIONS FOR ANALYSES 
 
For the secondary endpoint of objective response, data will be analyzed in an intention-to-treat 
manner and also in a modified intention-to-treat manner (including only those who received the TIL 
infusion plus at least one dose of IL-2). 
 
Safety analyses will be conducted on all participants that have received lymphodepleting 
chemotherapy.    
 
9.4 STATISTICAL ANALYSES 
 
9.4.1 GENERAL APPROACH 
This is a feasibility pilot trial of lymphodepleting chemotherapy followed by autologous tumor-
derived T cells for patients with advanced sarcoma. All patients will receive intravenous (I.V.) 
chemotherapy consisting of cyclophosphamide on Days – 7 and –6, fludarabine on Days –5 to -1, 
I.V. T cells on Day 0, and high dose IL-2 on Days 1 to 5. 
 
9.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S) 
The primary endpoints include feasibility and safety.    These will be analyzed as follows: 
• 
Feasibility is defined as a patient who can grow and expand T-cells. If it is feasible for at least 
3 patients out of 5 eligible patients, then this will be considered successful.  Upon successful 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
50 
completion, a subsequent, larger trial with efficacy endpoints will be designed.   We will track 
causes of failure to improve methods in the ultimate design of a trial with efficacy endpoints. 
• 
Safety will be analyzed by the record of adverse events as described in section 8.4.   AEs will 
be coded by CTCAE v5.0 and calculated counted once only for a given participant.  The data 
will be presented by System Organ Class (SOC), severity and frequency.  The start date, stop 
date, severity, relationship, expectedness, outcome, and duration will be reported for any 
grade ≥4 AE that does not resolve within 14 days of the last dose of IL-2.  There are two cutoff 
periods where AE would preclude continuation of therapy which are described in section 7.1 
and again below.     
o Lymphodepleting Chemotherapy Phase 
o Patients that develop an acute bacterial or viral infection during the lymphopenic phase 
of treatment will not continue to receive further treatments (TIL infusion and/or IL-2 
infusion).   Patients who experience any Grade 4 non-hematologic organ-specific 
adverse event (neurologic, pulmonary, cardiac, gastrointestinal, genitourinary, hepatic 
or dermatologic) that does not resolve prior to TIL infusion will not receive TIL infusion 
and subsequent IL-2 infusion. 
o Post-TIL Infusion IL-2 Phase 
o Patients who experience any Grade 4 non-hematologic organ-specific adverse event 
(neurologic, pulmonary, cardiac, gastrointestinal, genitourinary, hepatic or 
dermatologic) not felt due to sarcoma or a pre-existing condition will discontinue further 
IL-2 administration. Patients who develop a life-threatening Grade IV toxicity due to 
administration of high dose IL-2 such as: ventricular arrhythmia, life threatening 
infection, myocardial infarction, or permanently altered mental status will have IL-2 
permanently discontinued.   
We anticipate that up to 15 patients will be screened to obtain 5 eligible patients for the study. The 
eligibility criteria are defined as patients that meet criteria defined in section 5. Anticipated rate of 
patients to be screened is 1 patient per month, thus this study will need at most 10 months to accrue.   
The primary expected reason for screen fail is depressed cardiac function found on MUGA after 
consent due to prior Adriamycin exposure for this patient population. 
 
9.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S) 
There are two secondary endpoints for this trial, clinical response and persistence of the TIL infusion 
product.   These will be analyzed as follows 
• 
Objective response (OR) is defined as the patient being alive at Day 70 and tumor size 
evaluated using the RECIST 1.1 criteria to be a complete response (CR) or partial response 
(PR). Evaluations will be made by CT at 12 weeks after the cell infusion.    This will be 
reported as a proportion using both the intent-to-treat population and the treatment 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
51 
population.   The ITT population is defined as any patient that underwent a resection for TIL 
culture and the treatment population is defined as any patient that completes 
lymphodepletion, TIL infusion, and at least one dose of IL-2. 
• 
Persistence of the TIL infusion product will be reported individually per patient and collectively 
by responders and non-responders.   For this analysis, we will record the overlap in the top 50 
TCR clones between the infusion product (week 0) and the PBMC at the 1, 2, 3, 4, 5, and 6 
week time point, using the ImmunoSEQ™ (Adaptive Biotechnologies) platform.   We will 
construct a correlation table for the 21 unique pairwise comparisons for each patient and 
summarize the data.   Analysis will include the number and sequence of each productive 
unique Vβ and Jβ genes identified within each sample and the degree of clone sharing 
between samples of the same patient, using the TIL infusion product (week 0) as a reference 
point. 
 
9.4.4 SAFETY ANALYSES 
 
See section 9.4.2 as the safety analysis is a component of the primary endpoint analyses. 
 
9.4.5 BASELINE DESCRIPTIVE STATISTICS 
 
Basic demographic data will be obtained on the enrolled patients, including reason for screen fail in 
those patients that do not meet eligibility criteria. 
 
9.4.6 PLANNED INTERIM ANALYSES  
 
There are no planned interim analyses. 
 
9.4.7 SUB-GROUP ANALYSES 
 
There are no planned sub-group analyses. 
9.4.8 TABULATION OF INDIVIDUAL PARTICIPANT DATA 
 
Individual data will be listed by measure and time point according to the study calendar. 
 
9.4.9 EXPLORATORY ANALYSES 
 
Exploratory analyses will be as follows: 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
52 
• 
The phenotype of the preREP culture and infusion product relative to response will be 
reported.    We will report the frequency of T-cell subpopulation as CD3+, CD3+CD8+, 
CD3+CD4+, and CD3-CD56+ in the preREP and final infusion product. 
• 
Oncologic outcome 
o Progression-free survival (PFS), defined as the time from study entry to disease 
progression, relapse or death due to any cause, whichever is earlier, will be 
summarized with the Kaplan-Meier curve. Confidence intervals for the median and 
survival rates at different time points will be constructed if needed and appropriate. 
This secondary endpoint will be reported descriptively. 
o Overall survival (OS) is defined as the time from initiation of the study protocol to date 
of last patient contact or death due to any cause, whichever is latest. OS data will be 
analyzed and reported in the manner described for PFS. Additional survival follow-up 
for subjects who have progressed may continue until the patient is lost to follow-up or 
withdraws consent.  Additional OS analysis may be conducted periodically until the end 
of the study. The study will end once survival follow-up has concluded. 
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
 
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS 
 
10.1.1 INFORMED CONSENT PROCESS 
 
10.1.1.1 
CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED 
TO PARTICIPANTS 
Consent forms describing in detail the study intervention, study procedures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting 
intervention/administering study intervention. The following consent materials are submitted with this 
protocol: Informed Consent Document. 
 
10.1.1.2 
CONSENT PROCEDURES AND DOCUMENTATION 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Consent forms will be Institutional 
Review Board (IRB)-approved and the participant will be asked to read and review the document. The 
investigator will explain the research study to the participant and answer any questions that may arise. 
A verbal explanation will be provided in terms suited to the participant’s comprehension of the 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
53 
purposes, procedures, and potential risks of the study and of their rights as research participants. 
Participants will have the opportunity to carefully review the written consent form and ask questions 
prior to signing. The participants should have the opportunity to discuss the study with their family or 
surrogates or think about it prior to agreeing to participate. The participant will sign the informed 
consent document prior to any procedures being done specifically for the study. Participants must be 
informed that participation is voluntary and that they may withdraw from the study at any time, without 
prejudice. A copy of the informed consent document will be given to the participants for their records. 
The informed consent process will be conducted and documented in the source document (including 
the date), and the form signed, before the participant undergoes any study-specific procedures. The 
rights and welfare of the participants will be protected by emphasizing to them that the quality of their 
medical care will not be adversely affected if they decline to participate in this study. 
10.1.2 STUDY DISCONTINUATION AND CLOSURE 
 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause. Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party to the regulatory authorities. If the study is 
prematurely terminated or suspended, the Principal Investigator (PI) will promptly inform study 
participants, the Institutional Review Board (IRB), and sponsor and will provide the reason(s) for the 
termination or suspension. Study participants will be contacted, as applicable, and be informed of 
changes to study visit schedule. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
• 
Determination of unexpected, significant, or unacceptable risk to participants 
• 
Demonstration of efficacy that would warrant stopping  
• 
Insufficient compliance to protocol requirements 
• 
Data that are not sufficiently complete and/or evaluable 
• 
Determination that the primary endpoint has been met 
• 
Determination of futility 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the sponsor, IRB and/or Food and Drug Administration (FDA). 
 
10.1.3 FUTURE USE OF STORED SPECIMENS AND DATA  
Clinical data collected for this study will be analyzed and stored at MCC. After the study is completed, 
the de-identified, archived clinical data will be stored within the Moffitt Cancer Center Sarcoma 
Department, for use by other researchers including those outside of the study (with appropriate data 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
54 
sharing agreement in place). Permission to transmit de-identified data to other investigators will be 
included in the informed consent.  
With the participant’s approval and as approved by local Institutional Review Boards (IRBs), de-
identified biological samples will be stored within the Mullinax Lab with the same goal as the sharing 
of data with other investigators involved in ACT research at Moffitt Cancer Center. These samples 
could be used to research the causes of cancer, its complications and other conditions for which 
individuals with cancer are at increased risk, and to improve treatment.  
During the conduct of the study, an individual participant can choose to withdraw consent to have 
biological specimens stored for future research. However, withdrawal of consent with regard to 
biosample storage may not be possible after the study is completed.  
When the study is completed, access to study data and/or samples will be provided through the 
Principal Investigator after securing appropriate material or data transfer agreements as arranged by 
The Innovation Office. 
 
10.1.4 KEY ROLES AND STUDY GOVERNANCE 
 
Principal Investigator 
John Mullinax, MD 
MCC  
12902 Magnolia Drive, CSB-6, Sarcoma Department 
(813) 745-8736 
John.Mullinax@Moffitt.org 
 
Moffitt Internal Protocol Data Safety Monitoring Committee (PDSMC) as described section 6.4. 
10.1.5 SAFETY OVERSIGHT 
 
Serious Adverse Events: Serious Adverse Events (SAEs) from this protocol will be reported 
concurrently to the IRB and the study sponsor. The Protocol Monitoring Committee (PMC) will review 
these SAEs in accordance with the protocol-specific DSMP. This trial will be continuously monitored 
according to the Moffitt Cancer Center’s policy. A final safety and monitoring report will be submitted 
to the PMC within three months of the last patient treated. This protocol will be subject to periodic 
internal audits based on risk or as recommended by the PMC. 
 
10.1.6 CLINICAL MONITORING 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
55 
MCC’s Internal Monitors will periodically monitor regulatory documents and case report forms 
according to the protocol specific clinical monitoring plan. Monitoring will include review of data for 
accuracy, completeness, and source verification, reporting of SAEs, and adherence to the protocol, 
Good Clinical Practice (GCP) guidelines, and applicable regulatory requirements. 
 
10.1.7 QUALITY ASSURANCE AND QUALITY CONTROL 
The clinical site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation and completion. An individualized quality management plan will 
be developed to describe a site’s quality management. 
Quality control (QC) procedures will be implemented beginning with the data entry system and data 
QC checks that will be run on the database will be generated. Any missing data or data anomalies will 
be communicated to the site(s) for clarification/resolution. 
Following written Standard Operating Procedures (SOPs), the monitors will verify that the clinical trial 
is conducted and data are generated and biological specimens are collected, documented (recorded), 
and reported in compliance with the protocol, International Conference on Harmonisation Good 
Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices 
(GLP), GMP).  
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and 
regulatory authorities. 
 
10.1.8 DATA HANDLING AND RECORD KEEPING  
 
10.1.8.1 
DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Data will be captured in OnCore and/or MCC’s electronic Clinical Trials Management System. For 
each subject enrolled, the electronic CRF must be completed by the assigned data manager or other 
authorized study staff. Any paper forms should be typed or filled out indelible ink and must be legible. 
Errors should be crossed out but not obliterated, the correction inserted, and the change initialed and 
dated by the investigator or his/her authorized delegate. This also applies to records for those 
subjects who fail to complete the study. If a subject stops dosing or terminates from the study, the 
dates and reasons must be noted on the CRF. If a subject terminates from the study because of a 
dose-limiting toxicity, thorough efforts should be made to clearly document the outcome. 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
56 
Clinical data (including adverse events (AEs) and expected adverse reactions data) will be entered 
into Oncore, a data capture system provided by MCC.  Clinical data will be entered directly from the 
source documents 
10.1.8.2 
STUDY RECORDS RETENTION  
Study documents should be retained for a minimum of 10 years after the last approval of a marketing 
application in an International Conference on Harmonisation (ICH) region and until there are no 
pending or contemplated marketing applications in an ICH region or until at least 10 years have 
elapsed since the formal discontinuation of clinical development of the study intervention.  These 
documents should be retained for a longer period, however, if required by local regulations.  No 
records will be destroyed without the written consent of the sponsor, if applicable.  It is the 
responsibility of the sponsor to inform the investigator when there is no longer a need for these 
documents to be retained.  Permission must be acquired from the State of Florida for document 
destruction after the 10-year minimum record-retention period described above has elapsed. 
10.1.9 PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, International Conference on 
Harmonisation Good Clinical Practice (ICH GCP), or Manual of Procedures (MOP) requirements. The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As 
a result of deviations, corrective actions are to be developed by the site and implemented promptly.  
It is the responsibility of the site investigator to use continuous vigilance to identify and report 
deviations within 3 working days of identification of the protocol deviation, or within 3 working days of 
the scheduled protocol-required activity. All deviations must be addressed in study source documents, 
reported the Data Coordinating Center. Protocol deviations must be sent to the reviewing Institutional 
Review Board (IRB) per their policies. The site investigator is responsible for knowing and adhering to 
the reviewing IRB requirements. Further details about the handling of protocol deviations will be 
included in the MOP. Deviations must be entered into the Clinical Trials Management System 
(CTMS). 
 
10.1.10 
PUBLICATION AND DATA SHARING POLICY 
This study will be conducted in accordance with the following publication and data sharing policies 
and regulations: 
National Institutes of Health (NIH) Public Access Policy, which ensures that the public has access to 
the published results of NIH funded research. It requires scientists to submit final peer-reviewed 
journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance 
for publication. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
57 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-
Funded Clinical Trial Information and the Clinical Trials Registration and Results Information 
Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results information from 
this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish 
results in peer-reviewed journals. Data from this study may be requested from other researchers 10 
years after the completion of the primary endpoint by contacting the Principal Investigator.  
In addition, this study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-
funded research that generates large-scale human or non-human genomic data, as well as the use of 
these data for subsequent research. Large-scale data include genome-wide association studies 
(GWAS), single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, 
epigenomic, and gene expression data. 
 
10.1.11 
CONFLICT OF INTEREST POLICY 
The independence of this study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical. Therefore, any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to their participation in the design and conduct of this trial. The study 
leadership has established policies and procedures for all study group members to disclose all 
conflicts of interest and will establish a mechanism for the management of all reported dualities of 
interest. 
10.2 ADDITIONAL CONSIDERATIONS 
N/A 
 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
58 
10.3 ABBREVIATIONS 
 
ACT 
Adoptive cell therapy 
AE 
Adverse Event 
ANCOVA 
Analysis of Covariance 
BSA 
Body surface area 
CFR 
Code of Federal Regulations 
CIOMS 
Council for International Organizations of Medical Science 
CLIA 
Clinical Laboratory Improvement Amendments 
CLL 
Chronic lymphocytic leukemia 
CM 
Complete medium 
CMP 
Complete Metabolic Panel 
CMS 
Centers for Medicare and Medicaid Services 
CONSOR
Consolidated Standards of Reporting Trials 
CRF 
Case Report Form 
CRO 
Contract Research Organization 
CTF 
Cell therapy facility 
CTLA-4 
Cytotoxic T-lymphocyte–associated antigen-4 
CTMS 
Clinical Trial Management System 
DCC 
Data Coordinating Center 
DHHS 
Department of Health and Human Services 
DS 
Double strength 
DSMB 
Data Safety Monitoring Board 
eCRF 
Electronic Case Report Forms 
EBV 
Epstein-Barr virus 
ECOG 
Easter cooperative oncology group 
EKG 
Echocardiogram 
ELISA 
Enzyme-linked immunosorbent assay 
FDA 
Food and Drug Administration 
FDAAA 
Food and Drug Administration Amendments Act of 2007 
FEV 
Forced expiratory volume 
FTA 
Fluorescent treponemal antibody 
GCP 
Good Clinical Practice 
GCSF 
Granulocyte-colony stimulating factor 
GLP 
Good Laboratory Practices 
GMP 
Good Manufacturing Practices 
GWAS 
Genome-Wide Association Studies 
HEPES 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIPAA 
Health Insurance Portability and Accountability Act 
HLA 
Human leukocyte antigen 
HSA 
Human serum albumin 
HSV 
Herpes simplex virus 
HTLV 
Human T-cell leukemia-lymphoma virus 
IB 
Investigator’s Brochure 
ICH 
International Conference on Harmonisation 
ICH E6 
International Conference on Harmonisation Guidance for Industry, Good Clinical 
Practice: Consolidated Guidance 
ICMJE 
International Committee of Medical Journal Editors 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
59 
IDE 
Investigational Device Exemption 
IFN 
Interferon 
IL-2 
Interleukin 2 
IND 
Investigational New Drug Application 
IRB 
Investigational Review Board 
ISO 
International Organization for Standardization 
IV 
Intravenous 
MCC 
MCC 
MedDRA 
Medical Dictionary for Regulatory Activities 
MOP 
Manual of Procedures 
MSDS 
Material Safety Data Sheet 
MTD 
Maximum tolerated dose 
NIH 
National Institutes of Health 
NIH IC 
NIH Institute & Center 
NK 
Natural killer 
NS 
Normal saline 
OHRP 
Office for Human Research Protections 
PBL 
Peripheral blood lymphocytes 
PBMC 
Peripheral blood mononuclear cell 
PCP 
Pneumocystis carinii Pneumonia 
PI 
Principal Investigator 
PT 
Prothrombin time 
PTT 
Partial thromboplastin time 
QA 
Quality Assurance 
QC 
Quality Control 
RECIST 
Response evaluation criteria in solid tumors 
REP 
Rapid expansion protocol 
RPR 
Rapid plasma regain 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SMC 
Safety Monitoring Committee 
SMX 
Sulfamethoxazole 
SOC 
System Organ Class 
SOP 
Standard Operating Procedure 
TIL 
Tumor-infiltrating lymphocyte  
TK 
Thymidine kinase 
TMP 
Trimethoprim 
UP 
Unanticipated Problem 
VZV 
Varicella-zoster virus 
 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
60 
10.4 PROTOCOL AMENDMENT HISTORY 
The table below is intended to capture changes of IRB-approved versions of the protocol, including a 
description of the change and rationale. A Summary of Changes table for the current amendment is 
located in the Protocol Title Page.  
 
Version 
Date 
Description of Change  
Brief Rationale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
61 
 
 
 
 
 
 
 
 
 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
62 
11 REFERENCES 
 
1. 
Dudley, M.E., et al., Adoptive cell transfer therapy following non-myeloablative but 
lymphodepleting chemotherapy for the treatment of patients with refractory metastatic 
melanoma. J Clin Oncol, 2005. 23(10): p. 2346-57. 
2. 
Besser, M.J., et al., Minimally cultured or selected autologous tumor-infiltrating lymphocytes 
after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. J 
Immunother, 2009. 32(4): p. 415-23. 
3. 
Mullinax, J.E., et al., Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-
Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Frontiers in Oncology, 2018. 
8. 
4. 
Pilon-Thomas, S., et al., Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes 
After Lymphopenia Induction for Metastatic Melanoma. Journal of Immunotherapy, 2012. 
35(8): p. 615-620. 
5. 
Robbins, P.F., et al., Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma 
and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal 
of Clinical Oncology, 2011. 29(7): p. 917-924. 
6. 
Ahmed, N., et al., Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric 
Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin 
Oncol, 2015. 33(15): p. 1688-96. 
7. 
Kawakami, Y., et al., Identification of the immunodominant peptides of the MART-1 human 
melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating 
lymphocytes. J Exp Med, 1994. 180(1): p. 347-52. 
8. 
Seiter, S., et al., Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor 
metastases and cultured tumor-infiltrating lymphocytes. J Immunother, 2002. 25(3): p. 252-63. 
9. 
Dudley, M.E., et al., A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive 
Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic 
Melanoma. Journal of immunology (Baltimore, Md. : 1950), 2002. 25(3): p. 243-251. 
10. 
Dudley, M.E., et al., Adoptive cell therapy for patients with metastatic melanoma: evaluation of 
intensive myeloablative chemoradiation preparative regimens. J Clin Oncol, 2008. 26(32): p. 
5233-9. 
11. 
Koike, N., S. Pilon-Thomas, and J. Mule, Nonmyeloablative Chemotherapy Followed by T-cell 
Adoptive Transfer and Dendritic Cell-based Vaccination Results in Rejection of Established 
Melanoma. Journal of Immunotherapy, 2008. 31(4): p. 402-412. 
12. 
Antony, P.A., et al., CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ 
T helper cells and hindered by naturally occurring T regulatory cells. J Immunol, 2005. 174(5): 
p. 2591-601. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
63 
13. 
Klages, K., et al., Selective depletion of Foxp3+ regulatory T cells improves effective 
therapeutic vaccination against established melanoma. Cancer Res, 2010. 70(20): p. 7788-99. 
14. 
Song, S., et al., Significant anti-tumour activity of adoptively transferred T cells elicited by 
intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T 
cell/regulatory T cells in tumour. Clin Exp Immunol, 2010. 162(1): p. 75-83. 
15. 
Poehlein, C.H., et al., Depletion of tumor-induced Treg prior to reconstitution rescues 
enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J 
Immunol, 2009. 39(11): p. 3121-33. 
16. 
Wang, W., et al., PD1 blockade reverses the suppression of melanoma antigen-specific CTL 
by CD4+ CD25(Hi) regulatory T cells. Int Immunol, 2009. 21(9): p. 1065-77. 
17. 
Ahmadzadeh, M., et al., FOXP3 expression accurately defines the population of intratumoral 
regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood, 2008. 
112(13): p. 4953-60. 
18. 
Rosenberg, S.A. and M.E. Dudley, Adoptive cell therapy for the treatment of patients with 
metastatic melanoma. Curr Opin Immunol, 2009. 21(2): p. 233-40. 
19. 
Gattinoni, L., et al., Removal of homeostatic cytokine sinks by lymphodepletion enhances the 
efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med, 2005. 202(7): p. 
907-12. 
20. 
Pockaj, B.A., et al., Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in 
patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and 
correlation with response. Cancer, 1994. 73(6): p. 1731-7. 
21. 
Besser, M.J., et al., Clinical responses in a phase II study using adoptive transfer of short-term 
cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res, 
2010. 16(9): p. 2646-55. 
22. 
Crompton, J.G., N. Klemen, and U.S. Kammula, Metastasectomy for Tumor-Infiltrating 
Lymphocytes: An Emerging Operative Indication in Surgical Oncology. Ann Surg Oncol, 2018. 
25(2): p. 565-572. 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
64 
 
12 APPENDICES 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
65 
12.1 APPENDIX A 
Certificate of Analysis 
Cellular Therapy Product 
Documentation of review of release criteria for Tumor Infiltrating Lymphocytes (TIL) 
Principal 
Investigator 
 
 
 
Storage 
Temperature 
 
Protocol 
 
Final Product Volume 
 
Date/Time with 
Time zone 
manufactured 
 
Total Number of 
Viable Cells for 
Infusion  
(≤ 2E11 viable 
cells) 
 
Final Product 
Additives 
 
Expiration (24 
hours from 
Harvest) with time 
zone 
 
RELEASE CRITERIA 
TEST 
Method 
SPECIFICATIONS 
RESULTS 
Acceptable (Circle 
One) 
Tech 
Gross contamination 
Gram stain 
No organisms seen (NOS) 
 
Yes       No       N/A 
 
Sterility (From REP: Will not be final 
report) 
Sterility 
culture 
No growth to date 
 
Yes       No       N/A 
 
Endotoxin (Final Product) 
Endosafe 
<5 EU/kg 
 
Yes       No       N/A 
 
Mycoplasma contamination  
qPCR 
Negative 
 
Yes       No       N/A 
 
Identity  
Flow 
Cytometry 
≥ 90% CD3 +/CD45+ 
 
Yes       No       N/A 
 
Viability  
Dye Uptake 
> 70% viable cells 
 
Yes       No       N/A 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
66 
REVIEW OF FINAL PRODUCT FOR INFUSION SUITABILITY 
Product meets all release criteria (check one):      Yes       No (If ‘No’ is checked: explain below and obtain approval from Laboratory 
Director and Medical Director) 
_____________________________________________________________________________________________ 
____________________________________               _____________ 
Quality Management         or designee                                            Date 
 
If applicable: Comments: 
______________________________________________________________________________________________ 
_________________________________________   _______________                         
  Laboratory Director          or designee                                            Date                                     
 
 
 
Place Patient Label 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
67 
12.2 APPENDIX B 
Growth of TIL from Human Tumors 
Purpose: 
This technique is routinely used to grow tumor-infiltrating lymphocytes (TILs) and tumor cell lines from 
human solid tumors, including melanoma, sarcoma, non-small cell lung cancer, bladder cancer, renal 
cell carcinoma, colon adenocarcinoma, and penile squamous cell carcinoma. The method can also be 
used to grow lymphocytes from metastatic lymph nodes in these diseases. For reviews, see Yannelli, 
1991 (J. Imm. Methods) and 1996 (Int. J. Cancer), and Bessner 2010 (Clin Cancer Res). 
Procedure: 
Complete cell culture medium (CM) 
Human AB serum (Valley Biomedical) is heat inactivated, aliquoted into 10-mL tubes and then stored 
at -80°C for up to 6 months. One tube is randomly selected and tested for sterility. Complete medium 
(CM) for culturing TILs is prepared by supplementing RPMI-1640 (Invitrogen) with 10% human AB 
serum, HEPES (10 mM), Penicillin G (100 units/mL), Streptomycin (100 µg/mL), Gentamicin 
(50µg/mL), and -mercaptoethanol (5.5 x 10-5 M). Complete media will be labeled with patient name, 
MCC number, date of preparation, and expiration date (7 days after preparation). 
Deriving and Culturing TIL Cells from Tumor Explants 
Tumors are resected or biopsied in the operating room or clinic and placed in a sterile container 
containing RPMI. The remaining tumor is delivered to the Cell Therapies Facility (see Appendix C) at 
the MCC. 
For derivation of TILs, tumors are dissected with a scalpel or scissors into ~1 to 2 mm fragments in 
each of 3 dimensions. These fragments are then processed with enzyme media into a single-cell 
suspension, referred to as “tumor digest.” This digest is then cultured in a 24-well tissue culture plate 
containing 2 ml of CM supplemented with 6000 IU/mL recombinant human IL-2 (Prometheus Corp.). 
The plates are incubated in a humidified incubator at 37oC with 5% CO2 in air. 
Once the TIL cells have begun to grow, half of the medium in the well is replaced with CM containing 
IL-2 (6000 IU/mL). This is accomplished by removing approximately 1 ml of media from the top half of 
the well and replacing with fresh CM. Once the cells have expanded to confluence, the culture is split 
from 1 well to 2 wells by diluting the cells with equal volumes of CM containing IL-2. 
Cultures are continued until all tumor cells are eliminated and a cell number of ≥ 3 x 107 is obtained. 
This is typically accomplished in 21 to 28 days (5). If the TILs are not growing by 5 weeks and their 
concentration remains below 5 x 105/mL, the culture will not be used for the Rapid Expansion Protocol 
below for patient infusion. In this case, the cell culture will be discontinued. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
68 
All TILs from a given tumor will be tested individually against autologous tumor digest for tumor-
specific activity. Briefly, 1x105 TILs and 1x105 tumor cells will be placed in a single well of a 96-well 
plate with 300uL of CM. After incubation for 24 hours, the supernatant of the co-culture will be 
collected and placed into an ELISA assay for IFN-gamma. Those TILs that produced IFN-gamma (> 
250pg/mL) will be considered “reactive” for the next phase of cell product production 
Regardless of reactivity, the TIL cultures will be pooled and expanded using the rapid expansion 
protocol (REP). Before the REP, some of the TIL will be cryopreserved and stored for functional 
analysis or for later use in the REP if required. For cryopreservation, selected cells are mixed with an 
equal volume of freeze medium containing DMSO (Edward's Life Science) as cryoprotectant at a final 
concentration of 7.5% and frozen in a controlled-rate freezer (refer to TIL cryopreservation SOP - 
SOP SC2.1). 
During the initial TIL culture, the following in-process tests will be performed: 
1. 
14-Day Sterility (to be performed by MCC Pathology Laboratory or a 
designated licensed diagnostic laboratory): 
a. 
Within the first 24 to 72 hours after setup. 
b. 
As needed during the 5-week culture (if culture appears 
contaminated, etc). 
c. 
Final product at cryopreservation or when cells are brought to GMP for REP 
cultures. 
 
2. 
Endotoxin levels on final product at cryopreservation or when cells are brought to 
GMP for REP cultures. 
4. 
Viability on final product at cryopreservation or when cells are brought to GMP for 
REP cultures. 
5 
Cell count performed as needed during cell culture and on final product at 
cryopreservation or when cells are brought to GMP for REP cultures. 
Rapid Expansion Protocol 
TIL are washed in CM containing 50 g/mL gentamicin as sole antibiotic (this washing as well as the 
washing and freezing above removes any penicillin remaining from the original cultures) and 
expanded to large numbers for patient treatment by using a REP, as approved by the FDA for use at 
the at the NCI in protocols 98-C-95, 99-C-158 and 03-C-0162. The expansion is based on T-cell 
stimulation with the monoclonal antibody OKT3 (anti-CD3) and irradiated allogeneic feeder cells, 
mixed together. Human recombinant IL-2 is added to the culture 2 days after the culture is started and 
is included in all fresh medium added later to the culture. All final expansions of TIL (REPs) are 
performed in G-REX flasks (Wilson-Wolff) in therapeutic-grade AIM V culture medium (Invitrogen) 
containing streptomycin (50 µg/mL) and gentamicin (10 μg/mL). There is no penicillin in this culture 
medium and thus no potential problem for penicillin-sensitive patients. 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
69 
Feeder cells consist of a mixture of at least 3 allogeneic PBMCs. The source of these feeder cells in 
the REP are normal donors recruited specifically for this study; donors for these products have been 
screened for infectious diseases before collection of their product and determined to be negative 
before being used as feeders. 
Feeders (collected from a minimum of 3 different donors) will be thawed, pooled, re-aliquoted and 
cryopreserved until use. The pooled feeders are completely anonymized at the time of thawing and 
pooling. The pools are relabeled to include a unique identifier number. This is the only identification 
for these feeder cells. A product data sheet containing the feeder source identity information is 
retained by the Director of the Cell Growth Laboratory. 
On Day 14, the GREX-1000 flasks are harvested for infusion via centrifugation or membrane 
separation using a CytoMate machine (Nexell Therapeutics Inc.). During this concentration process, 
the TILs are washed with saline and resuspended in saline with 2.5% Human Serum Albumin (HSA) 
and 300 IU/mL of IL-2 for infusion. 
During the rapid expansion period, the following in-process QC testing is performed: 
1. 
Sterility at day 11 to 12 of REP (during the final 48 to 72 hours before harvesting 
and infusion. 
In addition, a series of tests is performed for research purposes: 
1. 
Cell-surface phenotype (for example, CD8, CD4, CD28, CD62L, and CD57) 
using flow cytometry analysis between days 7 and 12 of the REP. 
Product is released for clinical use based on the results of day 11 to 12 sterility tests (needs to be 
negative to date) as well as results of lot release testing as follows: 
1. 
Gram stain  
2. 
Endotoxin levels on final product  
3. 
Viability 
4. 
Visual Inspection 
Additional testing on final product (non-release criteria) includes 14-day sterility and mycoplasma 
testing.  
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
70 
12.3 APPENDIX C 
Cell Therapy Facility at Moffitt Cancer Center 
Leadership of Moffitt Cell Therapy Facility (CTF) is provided by Linda Kelley, PhD, Facility and 
Technical Director, James Mulé, PhD, Scientific Director, and Marco Davila, MD, PhD, Medical 
Director. CTF staffing consists of 40+ employees including 4 dedicated quality assurance specialists, 
4 technical project managers, 31 technical staff, 1 dedicated training specialist, 1 dedicated IT 
specialist, and 1 dedicated administrative and grants assistant. 
CTF is a newly constructed 10 000 square foot GMP-compliant state-of-the-art facility located in the 
M2GEN Building on the Moffitt McKinley Campus at 10902 N. McKinley Drive, Tampa, Florida, 33612. 
Moffitt McKinley Campus is approximately 0.5 mile from the main Moffitt Cancer Center (MCC) at 
12902 Magnolia Drive, where inpatient and outpatient treatments are provided. CTF maintains a 
1,000 square foot laboratory at MCC for the purpose of short-term storage of cryopreserved cell 
products and preparation of cell products for infusion. Receipt and shipment of fresh and 
cryopreserved cell products for off-site cell manufacturing occurs at MCC. 
CTF laboratory facilities consist of 10 Class 10 000 clean rooms, each equipped with biological safety 
cabinets, CO2 incubators, centrifuges and microscopes. A 1,000 square foot unclassified GTP 
laboratory is used for clinical procedures performed in closed systems. A separate quality control 
laboratory provides product testing including flow cytometry, quantitative PCR, ELISA, mycoplasma, 
endotoxin, gram stain, cell counts, and viability. Materials management and storage consists of 
separate quarantine receipt, kitting, and distribution locations. Liquid nitrogen storage of cell products 
occurs in new Chart MVE 1500 and 1800 series freezers in a secured 1 000 square foot facility. 
Source liquid nitrogen is supplied by an external 6 000 gallon bulk tank through vacuum-insulated 
piping under continuous electronic monitoring. All CTF equipment is monitored via the REES Centron 
Monitoring System. Quality Assurance compliance is facilitated with MasterControl quality 
management systems software. Laboratory data and information are documented with StemSoft Lab 
cell therapy management software. 
CTF provides manufacturing of safe therapeutic cellular products in support of standard-of-care 
cellular therapies for the Moffitt Bone Marrow Transplant and Cellular Immunology Program as well as 
novel, investigator-initiated clinical trials. Strategic alliances with industry partners are in place to 
advance development of translational cell therapy protocols and to facilitate clinical cell product 
manufacturing for national and international clinical trials. Cell therapy products manufactured include 
chimeric antigen receptor (CAR) T cells, tumor-infiltrating lymphocytes (TIL), gene- and peptide-
modified dendritic cell vaccines, tumor cell vaccines, and T regulatory cells (Treg). CTF has supported 
over 30 investigational new drug (IND) applications. 
Funding for CTF services is provided by the Moffitt Cancer Center Support Grant (P30 CA076292), 
payer billing and via charge-back accounts. CTF serves as one of 5 national NIH/NHLBI Production 
Assistance for Cell Therapy (PACT) Centers from 2016-2022 (HHSN 268201600013I). Compliance 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
71 
with standards set by the U.S. Food and Drug Administration (FDA), American Association of Blood 
Banks, and Foundation for Accreditation of Cellular Therapy (FACT) are consistently maintained. 
 
 


Adoptive Cell Therapy for Soft Tissue Sarcoma                 
 
 
Adoptive Cell Therapy for Soft Tissue Sarcoma               v09 January 22, 2022 
72 
12.4 APPENDIX D 
Table: Toxicity of Treatment of 283 Patients With Melanoma or Renal Carcinoma With 
High-Dose Bolus Interleukin 2* 
 
No. (%) of Courses by Diagnosis 
Toxic Effect 
Melanoma 
Renal Cell 
Total 
 
Chills 
42 ( 20%) 
40 ( 17%) 
82 ( 18%) 
Pruritis 
20 ( 10%) 
20 ( 8%) 
40 ( 9%) 
Mucositis 
0 ( 0%) 
2 ( 1%) 
2 ( 0%) 
Nausea 
78 ( 37%) 
92 ( 39%) 170 ( 38%) 
Diarrhea 
68 ( 33%) 
67 ( 28%) 135 ( 30%) 
Malaise 
37 ( 18%) 
28 ( 12%) 
65 ( 15%) 
Peak bilirubin, mol/L (mg/dL) 
1.7-34.2 (0.1-2.0) 
30 ( 14%) 
40 ( 17%) 
70 ( 16%) 
34.9-102.6 (2.1-6.0) 
126 ( 60%) 153 ( 64%) 279 ( 62%) 
104.3-171.0 (6.1-10.0) 
41 ( 20%) 
34 ( 14%) 
75 ( 17%) 
>171.0 (>10.0) 
12 ( 6%) 
11 ( 5%) 
23 ( 5%) 
Oliguria <80 mL/8 h 
39 ( 19%) 
60 ( 25%) 
99 ( 22%) 
Anuria <240 mL/24 h 
3 ( 1%) 
15 ( 6%) 
18 ( 4%) 
Weight gain, % of body weight 
0.0-5.0 
53 ( 25%) 
77 ( 32%) 130 ( 29%) 
5.1-10.0 
88 ( 42%) 
99 ( 42%) 187 ( 42%) 
10.1-15.0 
44 ( 21%) 
46 ( 19%) 
90 ( 20%) 
15.1-20.0 
16 ( 8%) 
13 ( 5%) 
29 ( 6%) 
>20.0 
8 ( 4%) 
3 ( 1%) 
11 ( 2%) 
Peak creatinine, mol/L (mg/dL) 
8.8-176.8 (0.1-2.0) 
98 ( 47%) 
44 ( 18%) 142 ( 32%) 
185.6-530.4 (2.1-6.0) 
105 ( 50%) 172 ( 72%) 277 ( 62%) 
539.2-884.0 (6.1-10.0) 
6 ( 3%) 
18 ( 8%) 
24 ( 5%) 
>884.0 (>10.0) 
0 ( 0%) 
4 ( 2%) 
4 ( 1%) 
Edema 
3 ( 1%) 
1 ( 0%) 
4 ( 1%) 
Respiratory distress 
4 ( 2%) 
14 ( 6%) 
18 ( 4%) 
Respiratory failure requiring intubation 
4 ( 2%) 
9 ( 4%) 
13 ( 3%) 
Pleural effusion 
3 ( 1%) 
2 ( 1%) 
5 ( 1%) 
Somnolence 
3 ( 1%) 
19 ( 8%) 
22 ( 5%) 
Coma 
1 ( 0%) 
9 ( 4%) 
10 ( 2%) 
Disorientation 
25 ( 12%) 
37 ( 16%) 
62 ( 14%) 
Hypotension 
97 ( 46%) 136 ( 57%) 233 ( 52%) 
Angina 
2 ( 1%) 
3 ( 1%) 
5 ( 1%) 
Myocardial infarction 
0 ( 0%) 
2 ( 1%) 
2 ( 0%) 
Arrythmias 
17 ( 8%) 
12 ( 5%) 
29 ( 6%) 
Anemia requiring transfusion, 
no. of units transfused 
0 
171 ( 82%) 182 ( 76%) 353 ( 79%) 
1-5 
35 ( 17%) 
47 ( 20%) 
82 ( 18%) 
5-10 
3 ( 1%) 
6 ( 3%) 
9 ( 2%) 
11-15 
0 ( 0%) 
3 ( 1%) 
3 ( 1%) 
Platelet nadir, cells x 109/L 
0-20 
7 ( 3%) 
9 ( 4%) 
16 ( 4%) 
20-60 
72 ( 34%) 
59 ( 25%) 131 ( 29%) 


 
 
                                                                              v09 January 22, 2022 
73 
 
 
60-100 
64 ( 31%) 
73 ( 31%) 137 ( 31%) 
>100 
66 ( 32%) 
97 ( 41%) 163 ( 36%) 
Infection 
9 ( 4%) 
9 ( 4%) 
18 ( 4%) 
Line sepsis 
3 ( 1%) 
6 ( 3%) 
9 ( 2%) 
Death 
0 ( 0%) 
3 ( 1%) 
3 ( 1%) 
 
TOTAL 
209 (100%) 238 (100%) 447 (100%) 
 
*Reference 1; includes only grade 3 and 4 toxicity except where detailed.